IMCAS

The principles behind AlidyaⓇ, the first injectable device ever designed to treat cellulite (Sponsored by MARLLOR BIOMEDICAL)

Objectives: Cellulite, more properly called gynoid lipodystrophy,remains one of the most daunting and intolerableaesthetic concerns for women. It affects up to
85%of women over 20 years of age, and it mostcommonly occurs on the buttocks and thighs,although it can also appear on the abdomen, hips,and other areas of the body1. Many treatmentoptions have been developed, from manual massageand topic therapies to the most sophisticatedenergy-based devices. However, the long-termefficacy remains a variable, subject to individualfactors and responses2.
In this scenario, and as the result of an intenseresearch on

Introduction: Alidya (Ghimas SpA, Casalecchio di Reno, Bologna,Italy) is the first class III, CE-marked, medical device,specific to treat cellulite (gynoid lipodystrophy). It isthe result of an intense research in the field ofcellulite performed by Prof. Pasquale Motolese, anItalian plastic surgeon and an innovator in the fieldof aesthetic medicine. Motolese identified the toxicaction of metallic elements, particularly iron andhemosiderin, provoked the peroxidation of cellmembranes, which in turn was responsible for thehyper-permeability of the venous microcirculation atthe hypodermis level3.
These findings

Materials / method: Alidya is supplied as a lyophilized powder, in vialscontaining 340 mg of powder, which need to bereconstituted with 10 ml of solvent prior to its use. Itis delivered using a multi-injection technique with a10ml luer/lock syringe and a 30G 4mm Meso Inject(Marllor Biomedical, S.r.L, Rimini, Italy) needles.
The standard protocol consists of 1 or 2 vials -depending on extension of the cellulite - every weekfor 7 weeks. Most patients will perceive improvementin the treated area after the third session. Aftercompletion of this protocol, it is advisable to do amonthly maintenance session. Prior to th

Conclusion: Unlike generic solutions that offer a one-size-fits-allapproach, Alidya presents a standard formulation withreplicable results, engendering a sense of trust andreliability among practitioners and patients alike. Also,what sets Alidya apart is its remarkable track recordspanning 11 years in the market, with scientific dataand ongoing research proving its efficacy, safety andlack of potentially serious side effects.
As the inaugural medical device meticulouslyengineered to address cellulite, Alidya exemplifies aparadigm of exactitude and therapeutic efficacy. Itsextensive presence in the market,

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): MARLLOR BIOMEDICAL

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): MARLLOR BIOMEDICAL

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): MARLLOR BIOMEDICAL

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: MARLLOR BIOMEDICAL

Treatment of dimpling from cellulite. (Sponsored by LOVE COSMEDICAL)

Objectives: Cellulite can be seen on the skin in widespread alterations of the skin surface and dimpling. The purpose of this study was to assess the effectiveness and safety of the manual subcision technique to treat dimpling from cellulite, using a specific class IIA medical device (Celluerase)

Materials / method: The multi-center observational study assessed 200 women treated in a single session for different dimpling, using manual subcision administered by Celluerase. Aesthetic outcomes were evaluated by the authors, and the patients as- sessed satisfaction levels.

Results: wo hundred women between 20 and 55 years were treated. The medical evaluation of patients saw improvements with an average score of 8.1, whereas the subjective evaluation by patients gave an average improvement score of 7.8. Adverse events were reported.

Conclusion: The study has shown the effectiveness and safety of the manual subci- sion in the treatment of dimpling. The device used, designed specifically
for this technique, has shown itself to be very helpful and effective in terms of practical use, aesthetic outcome and safety, with various advantages compared with other commonly used devices.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): LOVE COSMEDICAL

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): LOVE COSMEDICAL

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): LOVE COSMEDICAL

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: LOVE COSMEDICAL

Skin reconditioning compound for anti-aging. (Sponsored by LOVE COSMEDICAL)

Objectives: Facial aging involves all facial structures located at different levels: bones soft tissues and skin with a reduction of the extracellular matrix.
The aim of the study was to evaluate the efficacy of the injectable solution antiaging complex composed by non-reticulated hyaluronic acid (HA) and amino acids vitamins and antioxidants conveyed with mesotherapy technique in subjects with different expressions of aging.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): LOVE COSMEDICAL

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): LOVE COSMEDICAL

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): LOVE COSMEDICAL

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: LOVE COSMEDICAL

Supraperiosteal Filling Technique for Full Face Rejuvenation. (Sponsored by LOVE COSMEDICAL)

Objectives: Modern theories of facial aging are based on the concept that bone structures play an important role in inducing the typical aged face. This study evaluated the efficacy and tolerance of a new gel, which was injected over the periosteum in a standardized pattern in order to reduce the typical aging defects due to absorption and distortion of the bony facial tissue, replacing the deep support of the overlying soft tissue.

Introduction: The study was a multicentric, non-controlled clinical trial. Patients were treated in a single session with a standardized infiltrative technique where small boluses was released over the periosteum in 6 specific sites of each half-face. One hundred-78 subjects completed the study. The mean total amount injected was 5.4 ml (3.6 - 6.8 ml) per face per session. Treatment was judged by the subjects as well tolerated and not very painful. Recovery time was immediate, with a minimum disconfort during the first 24 hours (edema, pain, numbness) and it did not limit social life or other activities.

Results: Recovery time was immediate, with a minimum disconfort during the first 24 hours (edema, pain, numbness) and it did not limit social life or other activities. Rare adverse events described in literature did not occur.

Conclusion: The study demonstrated therapeutic success in 98.32% (evaluated by subjects) and 99.44% (evaluated by doctors) of the patients demonstrating the effectiveness of injection therapy. The medical device, employed with our specific standardized technique and with our range of dosage, was proved to be valid and safe.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): LOVE COSMEDICAL

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): LOVE COSMEDICAL

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): LOVE COSMEDICAL

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: LOVE COSMEDICAL

A review of Radiesse® as a regenerative aesthetic treatment (Sponsored by MERZ AESTHETICS)

Objectives: In skin tissue, the extracellular matrix (ECM) consists of components including collagens, elastin, and proteoglycans, and provides structure, elasticity, and hydration to the skin. Age-related degradation of the ECM can lead to loss of skin form and function. Regenerative aesthetics is a branch of regenerative medicine with therapies aimed at recapturing the youthful structure and function of tissue using the body’s own systems. Some injectable fillers used for aesthetic treatment contain exogenous materials that have been repeatedly shown to drive endogenous ECM regeneration. Calcium hydroxy

Conclusion: CaHA sustains cell proliferation and viability, which is associated with observed increases in collagen I and III, elastin, and proteoglycans, with minimal inflammatory cell activation. The quantity of regenerated ECM components restores favorable skin biomechanics, such as skin elasticity and firmness. Further studies investigating and comparing differences between injectable regenerative and biostimulatory treatments might help clinicians improve treatment paradigms.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): MERZ AESTHETICS

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): MERZ AESTHETICS

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): MERZ AESTHETICS

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: MERZ AESTHETICS

Safety and Effectiveness of Poly-L-lactic acid (PLLA-SCA) for the Improvement in Appearance of Cellulite – A Pilot Study (Sponsored by GALDERMA)

Objectives: To evaluate effectiveness and safety of Sculptra poly L-lactic acid injectable implant (PLLA-SCA) for improvement in appearance of cellulite in posterior thighs.

Introduction: PLLA-SCA stimulates collagen production and is mainly used in the face, but there is increased interest to also treat non-facial indications. This abstract presents data from a 12-month, pilot study in women ≥18 years with Grade 2-4 cellulite severity on the Galderma Posterior Thigh Cellulite Scale (GTCS), i.e. superficial to moderately deep depressions with undulations, who were treated with PLLA-SCA.

Materials / method: PLLA-SCA, reconstituted in 17 mL sterile water+1 mL 2% lidocaine, was injected immediately after preparation in the posterior thighs (max. 54 mL/thigh) at 1-3 treatment sessions, 4-6 weeks apart. Assessments included aesthetic improvement in cellulite appearance on the Global Aesthetic Improvement Scale (GAIS), GTCS, skin laxity, subject satisfaction and adverse events. Primary endpoint was GAIS at Month 9 after first treatment, assessed by investigators. Time to return to daily activities after each treatment, and pre-defined injection-site responses were collected in a 28-day subject diary.

Results: At Month 9, 28/29 subjects (97%) had aesthetic improvement of cellulite appearance on both thighs (GAIS), and 93% improvement on the GTCS. Improvement rates were overall high on GAIS (≥93% Months 2-12) and GTCS (79-100% Months 6-12), with improved skin laxity in all subjects at Months 6-12 (investigator-assessed). Most subjects were satisfied with thigh appearance (97%) and reported improved skin sagginess (93%) and firmness (97%) at Month 12. No treatment-related adverse events occurred and diary-events were mainly tolerable and transient, but remained 2-4 weeks for 17% of subjects.

Conclusion: Treatment with PLLA-SCA safely improved the appearance of cellulite at Month 9 (primary endpoint) in this pilot study, and aesthetic improvement remained through Month 12. This was further supported by high GTCS improvement rates and subject satisfaction. Study limitations include a small sample size and no control group.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): The presenting author was an investigator in the study, which was sponsored by Galderma. Investigator fees were paid to the clinic.

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Galderma

ReBorn 940nm IR Power LED Technological Breaktrough - A new source of energy for fat cells apoptosis (Sponsored by LIGHTFECTIVE)

Objectives: Body contouring, essential for aesthetics, traditionally relies on surgery, posing risks and recovery challenges. Non-invasive methods, including lasers, ultrasound, and radiofrequency, offer safer alternatives. Power LED 940 nm IR light using hyperthermic treatment, induces adipose apoptosis at 42-47°C, making it a promising technique for fat reduction.

Introduction: The Lightfective ReBorn system, utilizing 940 nm Power LED, delivers controlled energy for non-invasive fat reduction and body contouring. This case series aims to validate its ability to reach apoptosis temperatures safely.

Materials / method: Study Participants: Thirteen subjects (27-60 years,
females and males) with BMI ≤ 30 underwent single
ReBorn treatment. Exclusion criteria included large
visceral fat, skin laxity, and severe cellulite.
Study Procedure: Hyperthermic treatment lasted 35
minutes to all subjects, with LED energy gradually
increased for the first 10 minutes, the rest of 25
minutes were maintained with same cosistent energy.
Temperatures were recorded using a in-vivo
hypodermic thermocouple needle at a depth of 15 mm -
20 mm immediately after the treatment.

Results: Of the 35 applicator sites with
temperatures recorded, 82.86% (n=29)
reaching the desired temperature range
(mean: 44.91°C, median: 43.9°C). The
remaining 6 (17.14%) applicator sites did
not reach the desired temperature ranges.
It is expected that a delay in reading the
temperatures at these sites is responsible
for the reduced temperatures. No adverse
events were noted.

Conclusion: The ReBorn system, similar to 1060 nm lasers is able to reach the desired temperature range of 42-47oC, necessary to illicit adipose apoptosis during a 35- minute treatment session, with no recorded adverse events and within the patient’s comfort level.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): LIGHTFECTIVE

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): LIGHTFECTIVE

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): LIGHTFECTIVE

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: LIGHTFECTIVE

A multi-center trial evaluating a serum comprised of plant-based adaptogens targeting homeostasis and skin quality Status. (Sponsored by L'ORéAL DERMATOLOGICAL BEAUTY)

Objectives: Evaluate tolerability, efficacy and subject satisfaction in subjects with mild-to severe facial photoaging following twice-daily application of MYS serum over 12 weeks.

Introduction: § Skin naturally strives to maintain homeostasis
through complex communication pathways that help
skin respond and adapt to stress and aging.1,2
§ Optimal skin health relies on the skin’s ability to
maintain homeostasis and achieve balance in the
skin.3
§ Through adaptation and evolution, plants have
developed the innate ability to defend against
stressors.
§ These adaptogenic compounds are able to act on
multiple pathways and targets in the skin and support
skin in times of stress.4
§ A novel serum comprised of a proprietary, expert
system of plant-based adaptogens (P.A.T.H.
technology [MYS s

Materials / method: § This multi-center, open-label clinical trial was
conducted in subjects aged 45-65 years with FST I-VI
and mild-to-severe photoaging based on a 10-point
grading scale (3 [Minimum] to 7 [Maximum]).
§ Exclusion criteria included dermatological disorders
(e.g., severe acne vulgaris), autoimmune diseases,
acute illness, melasma or PIH, severe rosacea, facial
scarring, open wound/lesion or irritated skin in the
area to be treated; and, subjects who were pregnant,
lactating or planning a pregnancy during the study
period.
§ Subjects were deemed eligible for inclusion in the
study following a 4-week

Results: DEMOGRAPHICS
§ Fifty-three (53) subjects were enrolled and completed the
study.
§ The majority of subjects were female (92%) with a mean
age of 56 years.
§ Sixty-four percent (64%) of subjects were FST I-II, 21%
were FST III-IV, 15% were FST V-VI.
§ Sixty-six percent (66%) of subjects were Caucasian/White, 17%
were African American/Black.
§ Eight percent (8%) of enrolled subjects were Hispanic.
§ Eighty-one percent (81%) presented with a moderate
amount of photodamage.
SUBJECT SATISFACTION
§ Subjects reported high levels of satisfaction throughout the
study period.
§ After 4 weeks:
§ 98% noted

Conclusion: § A serum comprised of plant-based adaptogens (P.A.T.H technology) was purposefully developed to visibly improve skin quality and demonstrated significant improvements from baseline in Erythema, Skin Dullness, Skin Roughness/Texture (Visual), Pore Size, Uneven Pigmentation, and Global Skin Quality over 12 weeks.
§ Early, significant improvements from baseline occurred at Week 2 in Erythema, Skin Dullness, Skin Roughness/Texture (Visual), and Pore Size.
§ Significant improvements in Global Skin Quality from baseline were observed at Week 2 (13%), improving to 39% at Week 12.
§ Subjects reported

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: L'ORéAL DERMATOLOGICAL BEAUTY

INTERNATIONAL CONSENSUS ON ANTI-AGING DERMOCOSMETICS AND SKINCARE FOR CLINICAL PRACTICE USING THE RAND/UCLA APPROPRIATENESS METHOD (Sponsored by L'OREAL DERMATOLOGICAL BEAUTY)

Objectives: The objective of this international expert consensus was to provide a scientifically validated tool for recommending essential products for protection and repair and then work up to more advanced products for specific concerns.

Introduction: Consumers often seek recommendations from dermatologists on the best ingredients in dermocosmetics for their specific skin aging concerns.

Materials / method: A panel of 7 international experts reviewed 8 hypothetical case scenarios as representative examples of patients seen in daily dermatological consultations, covering different ages, skin issues (e.g., sensitivity, acne, melasma) and exposure to exposome factors, for both sexes and all Fitzpatrick skin types (FST).
The RAND/UCLA appropriateness method was used to obtain consensus. The experts completed a questionnaire to evaluate the appropriateness of 17 key ingredients in dermocosmetics on a scale from 1 (totally inappropriate: never used / risks greatly outweigh expected benefits), through 5

Results: A 30-year-old female FST IV has a 3-month-old son and recently noticed upper lip, bilateral jawline, and lateral forehead pigmentation. The presence of the dyspigmentation is emotionally distressing and is contributing to her post-partum depression. She has been avoiding public situations for the past month due to her appearance. She has ried several over-the -counter products without resuits. She is concerned that the pigmentation continues to darken despite her avoidance of the outdoors and wonders why this is happening. She does not wear photoprotection as she is dissatisfied with the sunse

Conclusion: We describe a simple, practical tool for use in daily dermatology consultations that is adapted to specific patient needs. This work provides recommendations to cover diverse and inclusive populations of patients, addressing all skin types and international needs.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: L'ORéAL DERMATOLOGICAL BEAUTY

CLINICAL EFFICACY OF A NOVEL DAILY FACE CREAM, WITH A PATENT-BASED ACTIVE, ON THE KEY SIGNS OF AGING (Sponsored by LABORATOIRES FILORGA PARIS)

Objectives: Skin is a protective and dynamic organ subject to different internal and external factors, including but not limited to chronobiological, hormonal variations,
lifestyle-related factors (environmental exposure, diet, etc.).

Introduction: These different factors are responsible for the accelerated deterioration of collagen and elastic
fibers, as well as an impact on skin barrier. These changes in the biomechanical properties appear on the skin's surface over time, leading to visible signs of
aging, such as wrinkles, dull complexion and loss of elasticity. Applying an anti-aging daily face cream can limit and reduce the aging induced damages. A
novel daily face cream has been developed which contains a patented repairing factor1. The efficacy was assessed in an in-vivo clinical study.

Materials / method: In the IRB-approved in-vivo clinical study², 36 Caucasian and Asian women aged from 43 to 65 of phototypes II-IV, were enrolled following the informed
consent process (U.S. Investigational Review Board, Inc, Miami, Florida). All subjects had face-wrinkles and mild to moderate skin slackness present. The daily
study face cream was applied twice a day to the entire face for 56 days. Efficacy was measured using bio-instrumentation (Cutometer®, Tewameter®,
Spectrophotopmeter-CM 700®) and image analysis (profilometry) after 7 days, 28 days and 56 days of application.

Results: Skin surface was quantitatively assessed by Primos 3D (Fig.1): a non
contact in vivo skin measurement device based on structured light
projection. In conjunction with a comprehensive 3-D measurement
and evaluation software, the sensor allows to evaluate skin
properties (i.e. wrinkle depth, skin roughness, etc.).
Compared to baseline in the clinical study, profilometry results show
a significant decrease of 9.6% on forehead (Fig.1A) and -13.3% on
crow’s feet (Fig.1B) wrinkles depth after 56 days of use.

Conclusion: The data from this clinical study shows global benefits of the daily
use of face cream on skin brightening/radiance, wrinkles,
smoothness, barrier, firmness and skin elasticity. This study
formulation presented a good skin tolerability on a variety of skin
types (normal, dry, oily, combination, sensitive). Furthermore, after
56 days of applications, 91.7% of subjects declared that they
preferred this cream to their usual cream.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): LABORATOIRES FILORGA PARIS

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): LABORATOIRES FILORGA PARIS

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): LABORATOIRES FILORGA PARIS

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: LABORATOIRES FILORGA PARIS

Observation of the aesthetic effect of Hyaluronic acid lips filler. (Sponsored by LABORATORIES HYAMED SA)

Objectives: To investigate the effect of hyaluronic acid lip fillers on aesthetic parameters of the lips.

Introduction: Fifty female attendees with a need for lip improvement from November 2021 to February 2022 were selected for the study, all of whom underwent HA filling of the lips, and the treatment effect, satisfaction, pain, and adverse effects were assessed in the immediate postoperative period, 2 weeks postoperative, and 1 month postoperative.

Materials / method: Lip filler: CD upper and lower lip red edge using a sharp needle along the edge of the red lip injection modification of sodium hyaluronate gel, bilateral upper and lower lip red edge of the total dose of 0.2 ~ 0.4 ml;® upper lip central lip bead 1, the lower lip side of the lip bead 2, the use of a sharp needle in the upper and lower red and white lip junction, the tip of the needle arrived at the lip bead localization, a single point to push the injection of modification of sodium hyaluronate gel, up and down the total injection dose of 0.3 ~ 0.6 ml;® the upper lip lip mound is located in t

Results: The aesthetic parameters of the lips improved significantly 1 month after treatment compared to the pretreatment period.The pain level of HA injections for lip fillers was mild and tolerable. All post-treatment adverse events disappeared completely within 1 month.

Conclusion: Hyaluronic acid for lip filler has outstanding benefits and high patient satisfaction.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): LABORATORIES HYAMED SA

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): LABORATORIES HYAMED SA

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): LABORATORIES HYAMED SA

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: LABORATORIES HYAMED SA

A multi-center, retrospective, chart review to evaluate the safety of poly-L-lactic acid injectable implant when used in non-facial areas (Sponsored by GALDERMA)

Objectives: This retrospective chart review study evaluated real-world data on safety of PLLA-SCA when used in non-facial areas.

Introduction: PLLA-SCA is an injectable poly-L-lactic acid implant, which gradually stimulates collagen formation. PLLA-SCA received US-approval for facial aesthetic use in 2009.

Materials / method: Subjects treated in a non-facial area with ≥2 vials of PLLA-SCA in ≥2 treatment sessions were eligible. Medical charts from 9 US sites were reviewed to collect demographics, treatment details and treatment-related adverse events (AEs) based on treatment sessions performed in 2012-2022.

Results: Among the 498 subjects included, most subjects had 2 (45%) or 3 (27%) treatment sessions, using on average 4.0 vials/treatment session. Reconstitution volumes were generally ≥10 mL for all treatment areas. Most common treatment areas were buttocks (61% of subjects), hip dip (17%), and decolletage (9%). Most treatment-related AEs were injection-related and mild or moderate. The most common AE was injection site bruising (5.0%), and AEs were mainly reported in the buttocks (4.0%) or posterior thigh (1.0%). Nodule occurrence was low (1 subject, 0.2%).

Conclusion: Based on this study, PLLA-SCA was well tolerated in real-world use for treatment of non-facial areas.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): The presenting author was an investigator in the study, which was sponsored by Galderma. Investigator fees were paid to the clinic.

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): I am an investigator and consultant for Merz, Revance and Allergan

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Galderma

Effects of the combination of Ca-Hydroxyapatite with NCTF® 135HA on the fibroblasts’ contractile force and collagen and elastin induction (Sponsored by FILLMED LABORATOIRES)

Objectives: The goal of this ex-vivo study was to compare the effect of each product as well as their
combination on the tissue collagen remodeling.

Introduction: Aging is characterized by skin alterations and can be macroscopically recognized because of wrinkles, loss of elasticity and flexibility, sagging and thinning of the skin. Today, there is a long list of different interventions for reversing the cellular effect of aging. One of the important treatment options is the soft tissue fillers. This category includes the classic fillers, the biostimulant and the biorevitalizing product. Recently, in a published article in JDD, the authors tried to dilute a biostimulant (Ca Hydroxyapatite, Radiesse®, MERZ, Germany) with a biorevitalizing solution (NCTF®

Materials / method: In vivo study on Human primary fibroblasts: GlaSBoxPlus®
GlaSBoxPlus®: the system consists of eight rectangular tanks. In each of them plunge two flexible blades, the lower parts of which are made up of grids on which the equivalent dermis clings during its polymerization. The equivalent dermis develops between two laminae to a rectangular shape that is slightly narrowed in the center (figure 1). This shape in classical mechanics is referred to as a "diabolo" shape. Under the influence of the contraction forces developed by the fibroblasts, the laminae become deformed. Their deformation is mea

Results: In vivo study on Human primary fibroblasts: GlaSBoxPlus®
A significant increase in contractile forces is observed in the presence of all products from Radiesse® at 1% compared to the control. This significant difference can be observed as early as 50 minutes for Radiesse®, at 1 hour and 50 min for NCTF® 135 HA and 2hr and 25 min for Crystalys® (figure 4). This results remain significant till 24 hours for all references (p<0.001) (figure 3). However, there is a significant difference between the combination of NCTF® + Radiesse® or NCTF® + Crystalys® (dilution 1:1) versus each product alone for

Conclusion: The combination of a biostimulant soft tissue filler such as Ca-Ha with a bio-revitalizing solution such as NCTF® 135 HA have a synergic effect on neocollagenesis and elastin production as well as the function of the human primary fibroblasts. This study revealed the 1 to 1 dilution but it is necessary to evaluate the effect of other dilutions as well. Although the clinical data published in JDD, it is necessary to evaluate the efficacy and safety on larger number of the subjects with longer follow up.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): FILLMED LABORATOIRES

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): FILLMED LABORATOIRES

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): FILLMED LABORATOIRES

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: FILLMED LABORATOIRES

Safety and longevity of Tri-Hyal® technology through comparative animal study and clinical trial. (Sponsored by FILLMED LABORATOIRES )

Objectives: In this poster, we have summarized the published data on the logevity and safety of the
TRI-HYAL® Technology compared to NASHA® and VYCROSS.

Introduction: Over the decades, products based on hyaluronic acid (HA), which can be naturally synthesized by fibroblasts and other resident cells in vivo, are widely accepted as dermal fillers due to their biocompatible, non-immunogenic, and noninflammatory properties. As a kind of glycosaminoglycan and a natural of the extracellular matrix, HA filler restores lost volumes of soft tissue as expected. Furthermore, it has been reported that cross-linked HA–based fillers may have additional effects, including stimulation of procollagen and various growth factors in aging skin in addition to their primary func

Materials / method: A total of 6 male BALB/c mice (6 weeks old) were obtained from the Experimental
Animal Research Center of the Fourth Military Medical University (Xi’an, China) in
strict accordance with the NIH guidelines for the care and use of laboratory animals
and approved by Animal Ethics Committee. Each mouse was subcutaneously injected
with 50 μL of ART FILLER® UNIVERSAL (AF), Restylane® (Res) and PBS on its dorsal skin (4 injections per product on each mouse). The sample collection of skin biopsies for each time point was performed on the same mouse on days 0, 30, 90 and 180 after injection. Subsequent

Results: To investigate the function of fillers in delaying the cell senescence, the Edu incorporation and CCK-8 assays were conducted on fibroblast cultured on cell plates precoated with AF and Res. It was observed that ART FILLER® UNIVERSAL significantly enhanced cell proliferation and viability compared to Restylane® (P<0.05; figure 5), although Res also moderately induced cell proliferation and increased cell viability compared with the vehicle1. The results of SA-β-gal as a biomarker for
aging, demonstrated that ART FILLER® significantly decreased the number of
positive-stained cells compared t

Conclusion: The TRI-HYAL® HA technology is a safe and efficient dermal filler with higher longevity
compared to NASHA, as measured by various tissue induction markers. The results of tissue inflammatory markers shows that this technology is safer than VYCROSS® as confirmed by 18 months of comparative split-face randomized clinical trials.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): FILLMED LABORATOIRES

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): FILLMED LABORATOIRES

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): FILLMED LABORATOIRES

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: FILLMED LABORATOIRES

The effects of Tri-Hyal® technology on different skin layers using High resolutional imaging technology. (Sponsored by FILLMED LABORATOIRES )

Objectives: The objective is to show the effects of TRI-HYAL® Technology via the high resolution imaging techniques as well as direct effect of the TRI-HYAL® HA on gene expression that regulates the metabolism of human primary adipocytes.

Introduction: Today, many doctors are using a cannula to ensure safety. However, when using a
cannula, hyaluronic acid could be injected between the immediate hypodermis and supra-periosteal levels. Although the injection is deep, we can also observe modifications in the superficial skin layers through the intercellular communications and cell mediators. For this reason, the authors tried to evaluate modifications of superficial skin layers using high-resolution imaging techniques (confocal microscopy, ultrasound and OCT). In addition, the effects of TRI-HYAL® HA were evaluated through ex-vivo studies and g

Materials / method: Clinical trial
20 subjects from the AF4 clinical trial were selected to be evaluated with high-resolution imaging techniques. All subjects were injected on the nasolabial fold with ART FILLER® LIPS (FILLMED, France).

In vivo reflectance confocal microscopy imaging
According to the method presented by Longo et al. in 2013, the acquisition was
performed through a mosaic cut at 4 levels of SC, epidermis, DEJ and superficial
dermis. The scoring was conducted by an expert dermatologist for all time points
using the Vivascope® 3000 (Vivascope, Germany).

Optical coherence tumography
The thorlabs’ t

Results: Clinical trial
In vivo RCM imaging: epidermis
The keratinocytes show an irrigular honeycomb pattern at baseline. However by
day 90 (3 months) after the injection of crosslinked HA even in immediate hypodermis, the structure of the keratinocytes becomes reggular and their borders are clearer with higher contrats. This may be due to CD44 receptors which are the specific receptors for HA and they are in commun with both
fibroblasts and keratinocytes. This result could explain the modification of the skin surface quality after the injection of HA fillers.

Conclusion: HA fillers based on TRI-HYAL® Technology have demonstrated proved effects on different layers of the skin from epidermis to hypodermis. Early injection of this HA filler could enhance skin quality by supporting all skin cells across different layers. This data should be supported with larger clinical trials.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): FILLMED LABORATOIRES

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): FILLMED LABORATOIRES

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): FILLMED LABORATOIRES

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: FILLMED LABORATOIRES

2-MERCAPTONICOTINOYL GLYCINE: A NEW MOLECULE THAT PREVENTS AND DECREASES UV-INDUCED PIGMENTATION (Sponsored by L'OREAL DERMATOLOGICAL BEAUTY)

Objectives: The objective of this study was to evaluate the anti-pigmentation efficacy of 2-MNG in preventing UV-induced pigmentation in phototype III skin

Introduction: Hyperpigmentation disorders are a frequent reason for dermatology consultations as they can impair quality of life.
The most frequent disorders are melasma, post-inflammatory hyperpigmentation and solar lentigos with increased
melanin content on top of other pathophysiologic features. The development of a key and safe ingredient to
manage facial skin tone heterogeneities is of great importance. The objective of this study was to evaluate the antipigmentation
efficacy of 2-MNG in preventing UV-induced pigmentation in phototype III skin.

Materials / method: Fourteen studies were conducted in women (between
20-50 years old) in Shanghai (China), Paris (France) and
Bucharest (Romania). For each study, 30 volunteers
phototype III were recruited. Several products were
applied (4 mg/cm2) on mini zones of the back, in a
randomized and blinded protocol, five days a week for
six weeks. Assessments were performed using Chromameter and
scales for pigmentation and erythema. All studies were
conducted in exactly same conditions and validated
with Ascorbic acid 7% standard pivot. A Bayesian
network meta-analysis established a large comparison
of 2-MNG 0.5% ant

Results: (i) 2-MNG 0.5% showed a significant antipigmentation
efficacy versus vehicle.
(ii) 2-MNG 0.5% in all associations has significant antipigmentation
efficacy than 2-MNG 0.5% alone.
(iii) All tests were validated with proven efficacy of
Ascorbic acid 7% when compared to its vehicle.
(iiii) Meta-analysis showed that 2-MNG 0.5% provide
statistically superior anti-pigmentation performance
compared to all selected standards.

Conclusion: This new ingredient delivers a very high efficacy versus recognized active ingredients from the market. It becomes a
promising approach to develop dermo-cosmetic products targeting main hyperpigmentation concerns of women
and men worldwide.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: L'ORéAL DERMATOLOGICAL BEAUTY

Preclinical and Clinical Evaluation of ACTV8SKN Actuator on Enhancing Skin Renovation: Impact on Collagen and Elastin Expression and Skin Quality Parameters (Sponsored by CONTRAD SWISS SA)

Objectives: A double evaluation, in vitro and in vivo, of a hydrogel-dispersed mixture of human synthetic biomimetic peptides (ACTV8SKN™ Actuator) to modulate COL1A1 and ELN fibroblast gene expression and to modify skin appearance and texture, in comparison with a similar GFs-enriched product.

Introduction: Skin appearance and texture are strictly dependent to a proper biosynthesis of biomolecules by fibroblasts. Fibroblasts continuously renovate the matrix
surrounding the dermal cell population by orchestrating the synthesis of collagen and elastin. Hence, they also support structural integrity and elasticity to the skin. The biosynthetic machinery is activated mainly by some proteins, among which growth factors. Ageing and environmental factors compromise the proper fibroblast functions, necessitating interventions that can restore their regenerative capabilities. The ACTV8SKN™ Actuator, powere

Materials / method: In vivo
- Human skin fibroblasts (ATCC CRL-2522) were maintained in MEM supplemented with 10% FBS and antibiotics.
- Cells were seeded, incubated for 24h and serum-starved for 24h. Treatment groups: negative control (untreated), positive control (TGF- ), Actuator/competitor treatments (same concentrations tested).
- Post-treatment, RNA was extracted and subjected to RT-PCR for COL1A1 and ELN expression quantification.

In vivo
40 healthy volunteers were enrolled for the study. 20 used the Actuator twice a day for 7 days, and 20 used a competitive peptide-base product, twice a day for 7 days.

Results: In vitro
- Actuator showed a 4.78-fold increase in COL1A1 after 24h (p<0.05), exceeding the positive control, whereas the CP did not significantly up-modulate the COL1A1 expression (fig.1).
- Actuator stimulated a 2.94-fold increase in ELN at 24h (p<0.05). The CP did not significantly up-modulate the ELN expression (fig.2).

In vivo
- Hydration: increase by 16.36% with Actuator (p=0.0002) Vs 14.53% with CP (p<0.0001) (fig.3).
- Firmness: increase by 19.58% with Actuator (p<0.0001) Vs 18.67% with CP (p<0.0001) (fig.4)
- Elasticity: increase by 21.93% with Actuator (p<0.0001) Vs 14.90% with CP (

Conclusion: This study shows the ability of the Actuator to significantly enhance the expression of collagen and elastin in human fibroblasts, with a superior efficacy at 24h when juxtaposed with another GFs-enriched product, and in a not concentration-dependent manner (data on files). These pre-clinical data paired with the study on volunteers, where the elasticity, hydration and firmness significantly improved after one week more than with the use of the CP, with a remarkable reduction of wrinkles, particularly around the periorbital area. Globally, this data supports the claim that the Actuator rapidly

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): CONTRAD SWISS SA

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): CONTRAD SWISS SA

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): CONTRAD SWISS SA

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: CONTRAD SWISS SA

Skin Tissue Modification with two different types of needling and radiofrequency (Sponsored by CAMPOMATS)

Objectives: Evaluation of different tissue modifications at the epidermal,
dermal and subcutaneous levels immediately after treatment with
different types of needling: non-energy-based microneedling (M),
microneedling combined with skin contact radiofrequency delivered
by a bipolar microcurrent circular probe (M-SRF), and microneedling
combined with deep radiofrequency delivered at the tip of the needle
(M-RF).

Introduction: Microneedling and radiofrequency (RF) are both treatments for skin pigmentation, textural problems, rhytides, and laxity caused by chronological aging or for acne scars and scars from injury or surgery. Often these treatments are combined in radiofrequency microneedling. Microneedling determines the thickening of epidermis and the skin remodelling by stimulating the fibroblasts responsible for collagen and elastin production by thousands of micro lesions through the epidermis into the papillary dermis. Radiofrequency energy is a form of electromagnetic current that can be delivered through var

Materials / method: In this study, we evaluate the efficacy of microneedling and superficial RF using two different needling lengths that allow two different penetration depths. The first needle depth (from 1.0 to 2.5 mm and named “microneedling”) reaches the papillary dermis determining slight bleeding, the second needle depth (0.3 mm and named “pricking”) is more superficial and penetrates the epidermis without bleeding. We enrolled 10 patients (age 46-55) with Glogau photo-damage classification scale type 2-3 for microneedling + SB-RF, each subject received three treatments in both cheek areas and superior li

Results: In microneedling + SB-RF group the subjects’ GAIS indicates the cheek skin quality as improved (20%) and much improved (80%) and superior lip skin quality as improved (37.5%) and much improved (62.5%). Patients’ satisfaction increases after the execution of all the three treatments. The Antera 3D camera recorded a mean reduction of cheek skin texture score of -9.65% in left cheek and -10.17% in right cheek and a wrinkle score reduction of -19,48% and -18.51% in left and right cheek respectively.
In pricking + SB-RF the subjects’ GAIS indicates skin quality as improved (42.9%) and much imp

Conclusion: The results this study confirm the efficacy of both microneedling + SB-RF and pricking + SB-RF in skin rejuvenation.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): CAMPOMATS

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): CAMPOMATS

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): CAMPOMATS

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: CAMPOMATS

Efficacious with minimal side effects : A novel treatment regimen for acne vulgaris using multifunctional ingredients. (Sponsored by ALUMIERMD)

Objectives: The primary objective was to evaluate the efficacy and tolerability of a non-prescription, active acne regimen in adult patients of all Fitzpatrick skin types with mild to moderate acne using both objective and subjective parameters. The secondary objective was to assess if this regimen would also mitigate post-acne sequelae and improve skin’s overall appearance.

Introduction: Acne is the most common skin condition and dermatologists are seeing a rise in the number of adult acne patients seeking treatment. There are numerous options available over the counter, although many formulations have tolerability issues and lack the cosmetic elegance desired by adult patients.

Materials / method: 35 male and female subjects ages 24-55 years with all Fitzpatrick skin types were enrolled in this single-site 8-week study to evaluate the effect of an acne treatment regimen that included a clarifying cleanser, balancing serum, and broad-spectrum sunscreen, which were formulated with unique and synergistic ingredients to mitigate active acne, restore barrier function, and reduce sequelae including PIH (post-inflammatory hyperpigmentation) and PIE (post-inflammatory erythema). At weeks 4 and 8, the dermatologist investigator evaluated each subject’s acne condition and subjects self-assessed t

Results: After 8 weeks of product use, the dermatologist investigator found that there was a statistically significant 63% decrease in inflammatory lesions (p<0.001) and a statistically significant 41% decrease in non-inflammatory lesions (p<0.001). There
was also a 51% statistically significant (p<0.001) reduction in the investigator global acne assessment (IGA). In addition, at week 8, the dermatologist investigator found
a 41% improvement in tactile smoothness (p<0.001), a 41% improvement in visual smoothness, a 39% improvement in skin softness (p<0.001), a 39% improvement in luminosity (p<0.001),

Conclusion: In this study, a simple, well formulated, cosmetically elegant active acne regimen was found to be highly efficacious and well tolerated when used by male and female adult acne patients of diverse ethnicities. In addition, the regimen improved cosmetic aspects of the skin including PIH and PIE which are important when treating adult acne sufferers.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): ALUMIERMD

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): ALUMIERMD

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): ALUMIERMD

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: ALUMIERMD

Ph III efficacy and safety data on relabotulinumtoxinA, an investigational liquid botulinum toxin for treatment of glabellar or lateral canthal lines (Sponsored by GALDERMA)

Objectives: To present results of two 6-month, Phase III clinical studies investigating relabotulinumtoxinA (relaBoNT-A) treatment of moderate-to-severe lines versus placebo. The READY-1 study investigated glabellar lines (GLs) (NCT04249583) and the READY-2 study lateral canthal lines (LCLs) (NCT04249687). Both studies evaluated efficacy and safety of treatment, and the primary endpoint for the EU analysis was responder rate at Month 1, defined as achievement of none-or-mild line severity on the investigator live assessment (ILA) scale for GLs at maximum frown or LCLs at maximum smile, respectively.

Introduction: RelabotulinumtoxinA (relaBoNT-A) is an investigational, innovative, complex-free, ready-to-use liquid botulinum toxin A that is manufactured from a proprietary C. botulinum strain and is free from human- or animal-derived components. The PEARL™ manufacturing process has no freeze-drying or precipitation steps, which protects and preserves the core neurotoxin in its natural conformation in liquid state throughout manufacturing, to maintain a high activity.

Materials / method: The studies were double-blind and placebo-controlled, with subjects randomized 3:1 to relaBoNT-A or placebo treatment. Assessments included line severity of GLs or LCLs by investigators and subject live assessment on separate scales (ILA, SLA), subject-reported onset of effect, subject satisfaction and adverse events (AEs). Responder rates of subjects achieving none-or-mild GL severity were calculated for the ILA and SLA scales separately. Time to return to baseline GL severity was calculated as a composite of both ILA and SLA scales.

Results: In both studies, none-or-mild ILA responder rates were significantly higher for relaBoNT-A vs. placebo at Month-1 (GLs: 96.3% vs 4.5%, p<0.001; LCLs: 87.2% vs 11.9%, p<0.001), remaining higher through Month 6 (GLs: 24% vs 2%; LCLs: 23% vs 7%, p≤0.002). 39% reported onset within 1 day in GLs, 34% in LCLs. Median time to return to baseline ILA/SLA was >24 weeks (end of study) in GLs, 24.7 weeks in LCLs. Both studies had high subject satisfaction (94% GLs; 87% LCLs, Month 1) and low rates of treatment-related AEs with relaBoNT-A vs. placebo (GL study: 3.6% vs. 0%; LCL study: 6.1% vs. 5.5%).

Conclusion: RelaBoNT-A treatment of GLs or LCLs was effective and safe, with high subject satisfaction and rapid onset. For both indications, the none-or-mild severity response was significantly higher after RelaBoNT-A treatment than placebo both at Month-1 (primary endpoint) and at Month 6. A long duration of effect was supported by Kaplan-Meier analyses showing median times to return to baseline of 24 weeks or longer for both indications.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): I was an investigator in one of the studies presented herein. Investigator fees were paid to the clinic by the study sponsor, Galderma.

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): I am an investigator and consultant for Allergan Aesthetics, Merz Pharma, Revance Therapeutics, and Hugel Pharma.

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Galderma

The evolving field of regenerative aesthetics (Sponsored by MERZ AESTHETICS)

Objectives: Regenerative aesthetics (RA) is an emerging field based on many of the principles of regenerative medicine (RM). In order to ensure that the development of regenerative aesthetics is based on accepted regenerative concepts and to optimize treatment strategies, it is important to establish clear definitions, fundamental aims and consider the impact of the predominant RA tissue environment RM focuses on the regeneration of injured or diseased tissue, while RA aims to restore youthful properties to aging, senescent tissue. The distinction is key in understanding how best to develop treatments for

Materials / method: Aims and methods: The current review suggests key concepts, definitions, and foundations of regenerative aesthetic approaches and examines current evidence supporting this. It considers the importance of the aging tissue environment, the essential regenerative goals of restored tissue structure and function and introduces the concept of regenerative scaffolds with a focus on CaHA. Current techniques in the field and promising future directions are also discussed.

Conclusion: Conclusion: Regenerative aesthetics is an evolving subfield of regenerative medicine. Establishing clear definitions, identifying the challenges of the aging soft tissue environment and re-evaluating current evidence in light of regenerative goals are vital for the continuing evolution of this medical field.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): MERZ AESTHETICS

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): MERZ AESTHETICS

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): MERZ AESTHETICS

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: MERZ AESTHETICS

An Evaluation of VYC-17.5L for Forehead Contouring: A Prospective, Open-Label, Post-Marketing Study (Sponsored by ALLERGAN AESTHETICS)

Objectives: This prospective, open-label, post-marketing study conducted in France evaluated the effectiveness and safety of the hyaluronic acid (HA) injectable filler VYC-17.5L for the improvement of forehead contouring.

Introduction: Forehead contouring, particularly in the supraorbital area and lower forehead, can be altered using injectable fillers. VYC-17.5L is a filler containing 17.5 mg/mL of HA with lidocaine (3 mg/mL) for treatment of skin depressions due to premature aging. Prior studies have demonstrated the safety and efficacy of VYC-17.5L in several facial areas including nasolabial folds and radial cheek lines, but little has been published on the effectiveness of VYC17.5L on the forehead. The purpose of this study was to evaluate the efficacy and safety of VYC-17.5L for forehead contouring.

Materials / method: Adult (≥18 years) subjects with irregularities of forehead contouring received VYC-17.5L in the forehead on Day 1 with optional touch-up on Day 14. Effectiveness was assessed by the proportion of subjects with an investigator-assessed Global Aesthetic Improvement Scale (GAIS) of “improved” or “much improved” from baseline at month 1 (M1). Secondary endpoints were subject-rated GAIS and FACE-Q Satisfaction with Facial Appearance. Injection site reactions (ISRs) and adverse device effects (ADE) were assessed throughout the study.

Results: 80 subjects completed the study. The primary endpoint was met: 98% of subjects showed improvement on the investigator GAIS. Subject GAIS scores were also improved. FACE-Q scores significantly improved from baseline (p<0.0001) and were sustained through month 12. Most ISRs were mild or moderate and resolved in ~1 week. 9 subjects (11%) reported ADEs with the majority being mild or moderate; the most common ADE was pain which resolved in <15 days.

Conclusion: This prospective, open-label study showed that VYC-17.5L was effective for improving forehead contouring, as demonstrated by improvements in investigator- and subject-rated measures. In addition, VYC-17.5L was well tolerated.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): Allergan Aesthetics, an AbbVie company

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Allergan Aesthetics, an AbbVie company. A. Gritti is an advisory board memebr, speaker, and trainer for Allergan Aesthetics, an AbbVie company

A Prospective, Open-Label Post-Marketing Study of Safety and Effectiveness of Ha/CaHA Filler for Midface Soft Tissue Augmentation: Interim Analysis. (Sponsored by ALLERGAN AESTHETICS)

Objectives: This open-label, post-marketing study of HA/CaHA conducted in France collected prospective data to support ongoing registration in Europe and other countries. These interim data include primary endpoint results.

Introduction: HA/CaHA is a soft-tissue hybrid filler intended for facial soft tissue augmentation. It consists of synthetic calcium hydroxyapatite (CaHA) microspheres (55.7% w/w) embedded in a cross-linked sodium hyaluronate gel (20 mg/mL HA). The Lidocaine version includes 0.3% (w/v) lidocaine HCl. Limited published prospective data on its safety and effectiveness are available.

Materials / method: Adults with moderate to severe midface volume deficit on Allergan Midface Volume Deficit Scale (MFVDS) received HA/CaHA in midface (main injection site), lateral face or jawline (optional) at initial treatment and optional touch-up at day 14. Primary endpoint was responder rate: ≥1-grade improvement from baseline on MFVDS at month 1 (1M). Secondary endpoints were investigator- & subject-rated Global Aesthetic Improvement Scale (GAIS) & FACE-Q Satisfaction with Cheeks & Satisfaction with Facial Appearance. Safety (injection site reactions [ISRs], adverse events [AEs]) was assessed throughout.

Results: 134 subjects completed the 1M visit; most had moderate midface volume deficit. The primary endpoint was met: 82.8% of subjects had ≥1-grade MFVDS improvement and responder rates remained high through month 9. Investigator and subject GAIS were improved. Both FACE-Q scale scores were improved. Most subjects (95.7%) had ISRs as expected of a HA and CaHA filler (eg, tenderness, pain); most were mild/moderate and resolved in <1 week. 52 subjects (37.1%) had treatment-related AEs (eg, injection site pain); most were mild in severity and resolved in <1 week. No treatment-related SAEs were reported.

Conclusion: Overall, most subjects treated with HA/CaHA achieved clinically meaningful improvement in midface volume deficit, GAIS, and subject-reported outcome measures. In addition, the safety results showed that HA/CaHA was well tolerated.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): Allergan Aesthetics, an AbbVie company

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Allergan Aesthetics, an AbbVie company; A. Gritti is an advisory board member, speaker and trainer for Allergan Aesthetics, an AbbVie company

Utilizing the AART methodology to maximize aesthetic treatment outcomes across different patient profiles (Sponsored by GALDERMA)

Objectives: To utilize the novel, standardized, systematic methodology of Assessment, Anatomy, Range and Treatment (AART™) for facial aesthetic treatments across different patient profiles using poly-L-lactic acid (PLLA-SCA; Sculptra®).

Introduction: Patients seek aesthetic treatments to address dissatisfaction with specific areas of their face. A full understanding of the patient’s reasons for seeking treatment is necessary to fully address their concerns and optimize treatment. AART™ is a novel tool for aesthetic clinicians that provides guidance for practitioners to perform a standardized, full facial assessment and allows an individualized treatment approach to holistically address a patient’s aesthetic concerns. Its use for facial aesthetic treatments across four different patient profiles using PLLA-SCA will be evaluated.

Materials / method: The use of AART™ in clinical practice was demonstrated across different patient profiles using four case studies. Following assessment, PLLA-SCA was the most appropriate treatment solution to address identified issues. PLLA-SCA was reconstituted with sterile water for injection and 2% lidocaine hydrochloride was added before injection. PLLA-SCA was injected subdermally into the appropriate facial region for the desired clinical outcome. The treatment outcomes evaluated were skin quality, glow, renewed volume and lifting. Adverse events were recorded throughout the treatment journeys.

Results: Each subject received PLLA-SCA at 2–3 injection sessions administered at 4–6-week intervals. In case 1, extensive acne scarring was considerably improved after 6 months and glow restored. In case 2, PLLA-SCA provided natural full face volumization with increased fullness and skin thickness/density in a post-bariatric patient. In case 3, PLLA-SCA helped correct volume deficiencies, restore firmness and address facial sagging. In case 4, PLLA-SCA improved structure and firmness to provide a lifting effect to slim a heavy face. No adverse events were reported in any of the patients presented.

Conclusion: The AART™ methodology applies a comprehensive and global approach to skin health and patient well-being while allowing a focused approach to different treatment outcomes and patient goals. In the four patients evaluated, PLLA-SCA delivered improvement in skin firmness plus it renewed facial volume, improved skin quality and thickness, restored skin glow, and provided a natural lifting effect. The AART™ methodology permits an individualized treatment approach in facial aesthetics and may be updated to include new advances in aesthetic medicine and address patients’ evolving needs over time.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): Galderma

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Galderma

Zionic rollactive massage and diathermy-based technology. Leads to adipose tissue reduction and contouring effect. (Sponsored by TERMOSALUD)

Objectives: This study aims to determine the eRcacy and safety of the high-power RF device ZIONIC in reducing adipose tissue, body contour and improving the dermatological properties of the skin.

Introduction: Non-invasive RF is one of the most promising and demanded technologies for skin tightening and body contouring Its high safety profile, combined with its eRcacy in the treatment of the main aesthetic conditions related to adipose tissue hypertrophy and dermal ageing, position these technologies as the best regarded ones by both medical professionals and patients There are several RF devices on the market aimed at reducing body fat and improving dermal properties

Materials / method: 25 healthy volunteers received 8 sessions of treatment (every 3 days) in the abdomen and flanks or tights. Standarized photographs, contour measurements, collagen content and fat layer thickness (DERMALAB Cortex Technology) were assessed before the treatment and z weeks after the last session.

Conclusion: The findings show that the treatment is a safe, effective, and well-tolerated non-invasive procedure that improves skin collagen, reduces fat tissue and leads to body contouring.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): TERMOSALUD

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): TERMOSALUD

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): TERMOSALUD

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: TERMOSALUD

Symmed, when versatility meets technology. (Sponsored by TERMOSALUD)

Objectives: This study aims to evaluate the effectiveness and versatility of treatments that can be performed by the SYMMED ELITE AESTHETIC device designed and developed by Termosalud SL.

Introduction: There dre currently numerous RF devices on the market, most of which Are used for body And fdCldl treatments. SYMMED ELITE AESTHETIC is d new generation non-invasive RF that cdn provide fdcidl, body dnd him
Anti-Ageing treatments, even in the presence
of fillers, neuromoduldtOrs dnd other injectable products that cm be Elected by heat. This is possible thinks to the EnhdnCell(R) system which modulates the RF providing high doses of energy without prodUcing temperature incredse.
EPectiveness dnd quality results dre gUdrdnteed in this versatile dermo-Aesthetic device.

Materials / method: In this poster, results of diPerent treatments following specific clinical pFotocOfs Are shown.

Hair growth stimulation: The scalp WCS treated to times ttwice d week) by using the wavy technology thdt incredses blood supply And follicle dctivdtion

Conclusion: SYMMED ELITE AESTHETIC treatment cm be applied safely on diPerent dreds.

In All cdses, in improvement in the dermal properties of the skin, incredse of dermal thickness dnd collagen content, iS observed dnd some of the most common concerns related with dging, sUCh ds presence of wrinkles And expression lines, And loss of hydFdtion And elasticity, Are reduced.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): TERMOSALUD

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): TERMOSALUD

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): TERMOSALUD

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: TERMOSALUD

Trichloroacetic acid based chemical peeling treatment of Fitzpatrick IV-VI skin phototypes: specifics and outcomes (Sponsored by SKIN TECH PHARMA GROUP)

Objectives: Targeted evaluation of the efficacy and safety profile of the Trichloroacetic acid-based chemical peeling - Skin Tech® Easy TCA® (CE-marked Medical Device Class IIa containing 15% TCA in Base Solution, Ex-tempora mixture) in patients with facial skin photoaging, pigmentation disorders and high skin phototypes was conducted in UK and South Africa. The study was part of the post-market surveillance of the product.

Introduction: Approximately 25% of the global population have Fitzpatrick IV-VI skin phototypes(1), characterised by increased amount of melanin content in the epidermis due to structural differences of melanosomes comparing with low skin phototypes. There are important considerations to take when performing chemical peels for medical and aesthetic indications on individuals with high phototypes.

Materials / method: Multicenter, open, single-arm, before-after study was performed in July-November 2023 in 3 study centers in United Kingdom and South Africa. Patients received a single full-face treatment with 15% TCA-based chemical peeling - Skin Tech® Easy TCA® - according to the Instructions for Use. The solution was applied in 2-3 coats to reach the peelings depth 3-4 according to Deprez’s classification(2). Sun avoidance during the study was strictly recommended. Skin photoaging clinical signs were tracked before (Day0) and after the treatment (Day7) using validated Alexiades-Armenakas scale(3). The asses

Results: Patients (n=16; 75% women, 25% men; aged 36-55 years; Fitzpatrick skin phototype III till VI) presenting photoaging of predominantly mild grade showed improvement in wrinkles, skin laxity, elastosis, dyschromia, erythema, telangiectasia, keratoses and texture. The photoaging grade demonstrated an average improvement of 23% compared to baseline measurements, achieving a 100% success rate.

Conclusion: Use of the 15% TCA-based chemical peeling - Skin Tech® Easy TCA® - in patients with skin photoaging and high phototypes provides desired results maintaining advanced safety and high efficacy. Minimization of potential risks is achieved through choosing
the right peel’s depths, proper application stictly following instructions for use, and professional supervision of the patient before and after the treatment.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): Skin-Tech Pharma Group

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Skin-Tech Pharma Group

Efficacy study of novel monophasic dermal implant containing cross-linked hyaluronic acid associated with amino acids for treatment of hands photoaging (Sponsored by SKIN TECH PHARMA GROUP)

Objectives: Investigation of a novel monophasic dermal implant containing crosslinked hyaluronic acid associated with amino acids (CE-marked Medical Device Class III, RRS® HA Long Lasting, Skin Tech Pharma Group, Spain) for its moisturising and volumising effects on the skin of the back of the hand in the treatment of photoaging. This study, which is part of the post-marketing clinical follow-up activities, aimed to evaluate the efficacy of the product in the treatment of the signs of ageing on the hands, with an additional focus on the evaluation aspects of safety profile.

Introduction: Following the face, the hands represent the second most prominent indicator of an individual’s age. Typically, subcutaneous fat loss accentuates the visibility of veins, tendons, and bony contours on the dorsum of the hand(1,2). Additionally, prolonged exposure to UV light throughout one’s lifetime renders the hands especially susceptible to cutaneous pigmentation alterations, commonly referred to as photo-damage(3). The most commonly conducted interventions involve filler injections, laser treatments, and fat grafting(4).

Materials / method: A multinational, multicenter, open-label, single-arm, before-after study conducted from July to November 2023 involved 10 study centers across Albania, Bulgaria, Georgia, Macedonia, Serbia, and the United Kingdom. The study included 60 clinical cases, with participants predominantly female (93%) and male (7%), aged between 56 and 65 years. The participants exhibited primarily moderate wrinkles and dull skin radiance.
A deep dermal injection was executed using a 22G x 70mm cannula (semi-rigid, blunt tipped), delivering 1.5 ml per hand through a retrograde technique. Employing 6-7 lines per hand

Results: A statistically significant reduction in the skin laxity grading scale was observed, starting with an initial mean value of 2.17 on Day 0 and decreasing to 1.83 on Day 30, reflecting a 16% decrease compared to baseline measurements. Regarding skin radiance, a notable transformation occurred from an initial mean value of 3.00 on Day 0 to 2.10 on Day 30, resulting in a 30% improvement by the study’s conclusion.
The Hand Grading Scale displayed a transformation of the severity of hand photoaging, commencing with an initial mean value of 2.77 on Day 7 and diminishing to 1.72 on Day 30, ultimately

Conclusion: The outcomes of the case reporting activity reaffirm the product’s remarkable efficacy while underscoring its exceptional safety profile. The use of novel monophasic dermal implant, RRS® HA Long Lasting, containing cross-linked hyaluronic acid associated with amino acids for hand rejuvenation proves to be a safe and effective non-surgical intervention, successfully reducing signs of photoaging on the dorsal hand while maintaining high safety standards.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): Skin-Tech Pharma Group

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Skin-Tech Pharma Group

Combination Treatment with Laser & Mask (Sponsored by SNJ)

Objectives: A New Concept of Whitening Treatment to Solve as an Inconvenience
One of the most common treatments for skin care in clinic is whitening. Although it has long been treating various pigment diseases, including Melasma, with various lasers and management equipment, it is true that it has felt a sense of regret and lack of results. In particular, Melasma is not easy to treat, and the patient's satisfaction is not high. There is also a risk of recurrence at any time. Treatment of pigmentation in clinical trials is not enough with a single laser, and should be done using complex methods such as

Materials / method: The mask has ample capacity of 28 ml, so the remaining ampoule can be used for high frequency and ultrasonic management. In fact, I have been treating patients for freckles and pigmentation with various laser treatments applying Tranexamic Acid, and Hydroquinone, but I was unsatisfied with the results. However, the combination of laser treatment - SNJ 1064 Q-Switched Laser (Finebeam) and mask use has increased satisfaction and improved treatment results. And this product contains Tea Tree ingredients, which is good for acne treatment. I do a lot of Photodyna m ic Therapy when treating acn

Results: It contains high concentrations of Hyaluronic Acid, so it is recommended to be used for several days after treatment, even if post-CO2 or Er:YAG Fractional Laser (SNJ Finexel) RF Needle treatment is necessary for scar treatment or enhancement of elasticity. The mask using lonzyme procedure with RF needle in patients with injection (Rosacea) significantly reduced the occurrence of hotness, erythema, pa pule, and pustulosis before and after use. Generally, it is recommended to use it for 3 to 7 days after laser treatment at home. It is recommended to attach once in the evening for 20 minutes. I

Conclusion: Treatment with Dr. Lucent mask and ionzyme can be combined with laser to enhance treatment effectiveness. Mask-ionzyme procedures are simple, do not require more personnel management, and slightly increase treatment time to enable advanced strategies. It contains rich whitening, antioxidant and moisturizing ingredients, so it can be used in various procedures in combination to reduce side effects and increase patient satisfaction.
Compared to the low-cost masks on the market, this product complements the component's shortage and is designed for professionals in clinical treatment. And I

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): SNJ

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): SNJ

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): SNJ

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: SNJ

Estyme® lips and Estyme® smooth, two Nnew HA dermal fillers for a global treatment of the lips and the perioral area. (Sponsored by SYMATESE)

Objectives: Over the past 3 decades, the use of hyaluronic acid (HA) dermal fillers has become the cornerstone for the correction of wrinkles, folds and volume loss. Based on 15 years’ technological innovations in combined solutions [syringe + gel] and the success of its 1st HA dermal fillers generation, SYMATESE developed its second product generation ESTYME® FILLERS with lidocaine, based on cold cross-linking process (C-HA PURE TECHNOLOGY by SYMATESE™) which is gentler and allows the HA gels to be matured over time, with the ability to adjust the HA gel characteristics resulting in products adapted to w

Materials / method: 72 subjects with mild to moderate lip fullness received ESTYME® LIPS in the lips.
61 subjects received ESTYME® SMOOTH in nasolabial folds (NLF) and lip
fine lines. 11 Subjects were injected only with ESTYME® LIPS and no one
was injected with ESTYME® SMOOTH alone.
Injections were performed with needle and/or canula.
Treatment session was unique without Touch-Up. The mean age of subjects
was 56 years [34 to 75 years] and 93% of subjects were women.

Results: Evolution of mean score improvement
Using a 5-point validated scale to evaluate lip fullness, and a 6-point validated scale to evaluate perioral fine lines and nasolabial folds severity, an improvement of each area was observed after injection and maintained over time without
touch-up. A meaningful improvement was still perceptible at 12 months for
all treated facial landmarks.

Evolution of responder rates
Based on the validated scales, the responder rates showed the subjects who had at least one grade improvement in lips, perioral fine lines and nasolabial folds. Responder rates were high af

Conclusion: The clinical study on two new HA dermal fillers showed an aesthetic improvement with an average of at least one improvement grade for each treated area after injection. The increase in lip fullness as well as the reduction in the severity of perioral fine lines and nasolabial folds were maintained over time.
For each injected area, notable improvement effects were still observed at 12 months for more than half of the subjects.

Global aesthetic improvement assessed by the subject himself and the investigator confirmed the excellent outcomes from the injection to 1 year. Although the treatment

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): SYMATESE

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): SYMATESE

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): SYMATESE

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: SYMATESE

The bidirectional cogged thread loaded into the specially designed flex-form cannula (Sponsored by AYOON MEDI)

Objectives: The drooped nasolabial fold is corrected using the cogged thread loaded on the flex-form cannula, and its usefulness is verified.

Introduction: Recently, various attempts have been made to correct the drooping of the nasolabial fold with threads. However, it is difficult to insert a sufficiently long cogged thread due to the natural convex curvature of the anterior mala area. Using a bi-directional cogged thread loaded on a flexed cannula designed in a special shape devised by the author, the nasolabial fold was corrected and its usefulness verified.

Materials / method: The cannula was designed to
fit the covex contour of the
anterior mala. After trial and
error, a 10cm sized cannula
that was bent 160 degrees 3
times was completed, and a
PLACL bidirectional molding
cogged thread was loaded
onto the cannula, which was
then used for naso labial fold
correction. Two methods were
used. The first low to high
method is to make an insertion
point at the most protruding
part on the just lateral
side of the nasolabial fold,
insert two threads, and then
advance to the sideburn. The
second, high to low, is a
method of making two different
inserting points on the
sidebur

Results: A total of 214 patients were
operated on from March 2021
to May 2023, and the majority
showed excellent results in
the evaluation conducted one
week after the procedure. In
terms of the degree of correction,
it was clearly improved
compared to the existing
thread lifting.
Complications were reported
in 16 cases of PIH that occurred
at the inserting point
of the nasolabial fold, and improved
in 6 cases with additional
laser treatment and in
others without additional
treatment. Dimpling occurred
in 4 cases and was resolved
with filler. In the high to low
approach, an infection presumably
caused

Conclusion: The correction of the nasolabial fold using the cogged thread loaded on the flexed cannula is very useful and is expected to be applicable to other areas with curvature.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): AYOON MEDI

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): AYOON MEDI

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): AYOON MEDI

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: AYOON MEDI

Retrospective case series following patients treated with a combination of CPM-HA and CaHA fillers (Sponsored by MERZ AESTHETICS)

Objectives: Clear guidelines for practitioners who want to implement such methods are lacking. In this case series, we provide examples showcasing real-world applications of combination use of CPM-HA and CaHA.

Introduction: •Combining aesthetic treatments has become an increasingly popular way to achieve patient-personalized results.
•A retrospective case study examined 4 patients who received treatments of both fillers composed of cohesive poly-densified matrix hyaluronic acid (CPM-HA; Belotero®, Merz Aesthetics GmbH, Frankfurt am Main, Germany) and calcium hydroxyapatite, (CaHA; Radiesse®, Merz North America, Raleigh, NC) either in the same session or series of sessions.

Materials / method: •Data were gathered from the charts of 4 international physicians that utilized treatment plans including both CaHAand 1 or more of 3 types of CPM-HA fillers (CPM-HA/V, Belotero® Volume; CPM-HA/I, Belotero® Intense; CPM-HA/B, Belotero® Balance). The study included adults over 30 years of age who provided informed consent for treatment, data collection and photo release for publication.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): MERZ AESTHETICS

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): MERZ AESTHETICS

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): MERZ AESTHETICS

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: MERZ AESTHETICS

The use of magnetic stimulation for the treatment of female urgency urinary incontinence (Sponsored by ISKRA MEDICAL)

Objectives: The aim of our study was to assess the efficacy of MS in the treatment of urgency urinary incontinence (UUI). The efficacy of MS was assessed with the score of ICIQ-SF (International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form), which is the only validated questionary in Slovene language, and we compared our treatment group with the sham treatment group to assess the placebo effect in the treatment of UUI with MS.

Introduction: UI is differentiated according to the underlying pathophysiological mechanisms and is divided into the most common types: stress (SUI), urgency (UUI), mixed (MUI), and “overflow” UI. Deciding on a conservative or surgical treatment approach, which vary according to the type of UI, depends predominantly on the type and severity of UI and on comorbidities. Conservative treatment should be exhausted first. MS is one of the methods used in the conservative treatment of UI, which is based on Faraday’s law of induction. It follows the principle of magnetic induction, which triggers depolarization of

Materials / method: In the first part of our research, we conducted a systematic review of the available literature on the efficacy of MS in the treatment of UI. In the second part we conducted a prospective randomized, sham-controlled trial (RCT) that took place at the Division of Gynaecology and Obstetrics at the University Medical Center of Ljubljana. We included 40 female patients with UUI who were randomized in active and sham-controlled group in a ratio 2:1 in favour of the
active group. We treated the patients with 12 treatments (2-3 treatments per week for 30 minutes). After 6 months, the patients complet

Results: Based on the findings from the systematic review, it can be concluded that MS is a successful non-invasive conservative method for treating UI. Future studies are necessary, all of which should include a large sample size, a control group, an optimal research protocol, pretreatment analyses, standardization, and longer follow-ups. According to our RCT, we were able to prove a statistically significant difference between the active and sham group; moreover, we prove a statistically significant difference within the active treatment group before and after the treatment with MS. The score of the

Conclusion: Among the conservative UI treatment methods, MS is one of the safest methods for the patient and as such a suitable first step in treating UI. Active MS therapy significantly improves UUI symptoms versus sham treatment and should be considered as a conservative treatment option for UUI patients.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): ISKRA MEDICAL

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): ISKRA MEDICAL

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): ISKRA MEDICAL

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

and status : ISKRA MEDICAL

This work is presented thanks to the support of: ISKRA MEDICAL

Attraction of fibroblasts by Micro-Focused Ultrasound (MFU-V) (Sponsored by MERZ AESTHETICS)

Objectives: Micro-Focused Ultrasound with real-time Visualization (MFU-V, Ulthera®, Merz North America, Inc.,Raleigh, NC, USA) is the first FDA-approved device for non-invasive skin lifting treatment. The MFU-V uses transducers with different frequencies to target specific depths in the skin ranging of 1.5, 3.0 and 4.5 mm, inducing thermal coagulation points (TCPs) at precise intervals in the respective area. Thereby, stimulating the tissue for efficient neocollagenesis and ECM-remodeling resulting in subsequent skin lifting effects.

Introduction: The current study investigates the underlying mode of action of MFU-V, focusing specifically on the attraction of fibroblasts to the treatment area.

Materials / method: MFU-V treatment was used in an in-vivo study with transducers targeting 1.5 mm and 3.0 mm depths following histomorphometric analysis of tissue sections 14 and 90 days post treatment.
Sections were paraffin embedded and stained for immunohistochemistry (IHC) with Hsp47, a marker of activated and ECM-producing fibroblasts and a collagen-specific chaperone that plays an essential role during collagen biosynthesis1.
Subsequent analysis of Hsp47-positive fibroblasts within TCPs and within a 300 µm expansion around TCPs.

Results: • The effects of MFU-V in the skin can be visualized at 1.5 and 3.0 mm depth by IHC using Hsp47 antibody (A, B).
• After 90d, the total number of cells per mm² increased by 2.4 fold compared to the surrounding tissue (C, ANOVA Šídák‘s multiple comparison ****p<0,0001).
• At 90d post TCP, the number of Hsp47- positive fibroblasts within the TCP is greatly increased compared to the expansion area and compared to 14d (D, ANOVA Šídák‘s multiple comparison ****p<0,0001 ).

Conclusion: • The current study shows that MFU-V generates TCPs that strongly attract ECM-producing fibroblasts within 90d after treatment.
• Attracted fibroblasts were Hsp47 positive, indicating a TCP-mediated tissue lifting via neocollagenesis.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): MERZ AESTHETICS

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): MERZ AESTHETICS

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): MERZ AESTHETICS

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: MERZ AESTHETICS

Pre clinical and clinical evaluation of lifting effect of the synergic association between biotechnological collagen and lupeol extract (Sponsored by MARTIDERM)

Objectives: To design, formulate and determine the efficacy and tolerance of a cremigel containing 1% biotech collagen supplemented with lupeol.

Introduction: Skin aging is a natural process caused by intrinsic changes and extrinsic damage. Most of the changes occur in the dermis, composed mainly of a collagen-rich extracellular matrix. Its synthesis decreases over time and the existing fibrils become disorganised, with the consequent loss of firmness and appearance of flaccidity.

Materials / method: ACTIVE INGREDIENTS
BIOTECH COLLAGEN
Is a bio-mimetic collagen (COL1A2), 100% DNA sequence matches with the specific chain of Human COL1A2.
Benefits:
▪ 15 times smaller than marine collagen
▪ reaches deeper layers of the epidermis
▪ 3 times more effective than marine collagen

LUPEOL EXTRACT
Active molecule extracted from the sweet white lupine seed.
Benefits:
▪ stimulates synthesis of high-quality collagen
▪ improves the skin’s elasticity, remodels and firms sagging skin areas.

The lifting effect of the synergistic combination of active ingredients was evaluated through preclinical and clinic

Results: IN VITRO STUDY
A 2.5-fold increase in collagen I levels compared to the control and a 78% increase compared to the lupeol-free treatment.

IN VIVO STUDY
1) Instrumental evaluation: lifting effect
The average improvement in the definition of the facial oval and the best voluntary are presented:

2. Skin Tolerance
The dermatologist determined very good skin tolerance.

3. Subjective evaluation
A high % of volunteers reported that cosmetic qualities were very good and that continued use firmed their skin and reduced sagging.

Conclusion: The synergistic combination of collagen and lupeol is a safe and effective option that is well received by users to combat the signs of skin aging, since it boosts collagen synthesis and improves facial oval definition.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): MARTIDERM

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): MARTIDERM

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): MARTIDERM

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: MARTIDERM

Physical properties of diluted Radiesse® (Sponsored by MERZ AESTHETICS)

Objectives: The rheological properties, cohesivity and extrusion force of calcium hydroxylapatite in a carboxymethylcellulose gel carrier (CaHA-CMC, Radiesse®; Merz North America, Raleigh, NC) at various dilutions were investigated. This study highlights the significant impact of aqueous dilution on the rheological and potential regenerative properties of CaHA-CMC. The findings support the clinical application of tailored dilutions to achieve desired outcomes, providing versatility and safety for aesthetic applications.

Introduction: The G’, G”, viscosity (η*), and tan(δ) were analyzed for each dilution using an Anton Paar Oscillatory rheometer (Anton Paar GmbH, Graz, Austria). The extrusion force of undiluted CaHA-CMC was measured directly out of the injection syringe after attachment to a 27 G ¾” Terumo thin wall needle. Diluted CaHA-CMC was transferred back into the original CaHA-CMC syringe immediately after mixing and the extrusion force was measured using a 27 G ¾” needle. The cohesivity of each dilution and undiluted CaHA-CMC was determined by the weight drop test. The related G’ values were plotted against known co

Materials / method: The G’, G”, viscosity (η*), and tan(δ) were analyzed for each dilution using an Anton Paar Oscillatory rheometer (Anton Paar GmbH, Graz, Austria). The extrusion force of undiluted CaHA-CMC was measured directly out of the injection syringe after attachment to a 27 G ¾” Terumo thin wall needle. Diluted CaHA-CMC was transferred back into the original CaHA-CMC syringe immediately after mixing and the extrusion force was measured using a 27 G ¾” needle. The cohesivity of each dilution and undiluted CaHA-CMC was determined by the weight drop test. The related G’ values were plotted against known co

Results: CaHA-CMC dilution significantly impacted the rheological and mechanical properties, consistent with previous observations. Results revealed a significant decrease in G', η*, and increase in tan δ with increasing dilution. Cohesivity decreased dramatically with dilution. Extrusion force changes were statistically significant between the undiluted and 1:1 dilution points; however, beyond the 1:1 point, incremental dilutions did not yield significant changes in this parameter. The dilutional rheomodulation of CaHA-CMC and subsequent decrease in G’ is correlated with dilution-dependent increases i

Conclusion: The rheological characteristics of CaHA-CMC gels are significantly impacted by aqueous dilution of the product. Compared to undiluted product, hyperdilution substantially decreases the product’s resiliency and cohesivity. However, the dilutional alterations in the product’s rheological profile exist along a continuum between maximal filler resiliency and optimal bioregenerative effects that may be harnessed clinically to enhance the suitability of the product to a range of applications. This dilutional rheomodulation of CaHA-CMC thus offers a potentially valuable tool increasing product versat

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): MERZ AESTHETICS

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): MERZ AESTHETICS

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): MERZ AESTHETICS

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: MERZ AESTHETICS

Evidence-based science behind the diffusion and spread of abobotulinumtoxinA (Sponsored by GALDERMA)

Objectives: This presentation aims to summarize the scientific evidence of diffusion or spread of abobotulinumtoxinA (aboBoNT-A) as compared to other commercially available botulinum toxin A (BoNT-A) formulations.

Introduction: There is a myth that different formulations of BoNT-A approved for aesthetic use may have different diffusion and spread characteristics. Diffusion is a passive movement toward a lower concentration gradient (Fick’s law) and is dependent on number of injected molecules (dose), while spread is mainly affected by the injector (e.g. volume/point, injection speed, injection technique/angle).

Materials / method: Publications exploring diffusion/spread of aboBoNT-A and other BoNT-A products were reviewed. These included in vitro experiments on how pH affects the BoNT-A complex; studies to measure diffusion/spread into adjacent muscles of BoNT-A products (in mice) and of aboBoNT-A in escalating doses (injected into foot muscles, extensor digitorum brevis (EDB), in human volunteers). Safety results from clinical studies of glabellar line (GL) treatment were reviewed for evidence of spread, e.g. ptosis events, on-label and when using high doses up to 125U of aboBoNT-A and at different injection volumes.

Results: At physiological pH in vitro, complex proteins dissociate from the core toxin within minutes. In mice, BoNT-As of various complex sizes and formulations showed no difference in diffusion/spread into adjacent leg muscles. In healthy subjects, a randomized GL study using 50-125U aboBoNT-A or placebo showed a low, not dose-related ptosis rate, 0-2.5%. In healthy subjects, when injecting EDB at different doses no spread of aboBoNT-A was observed in nearby muscles. Another GL study revealed similar safety profiles with no distant spread when doubling the aboBoNT-A volume from 0.05mL to 0.1mL/point.

Conclusion: Evidence from in vitro, animal experiments and human trials show that diffusion of BoNT-A is not related to complex size, and that the risk of spreading of aboBoNT-A to other muscles is comparable to other BoNT-A products. AboBoNT-A GL treatment is well tolerated at a large range of doses (50 to 125 U) or volumes per injection site, with a low incidence of ptosis comparable to that of other BoNT-A products.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Effectiveness and Safety of a New NASHA-HD Hyaluronic Acid Injectable, HA-SHA, for Augmentation and Correction of Chin Retrusion (Sponsored by GALDERMA)

Objectives: To assess effectiveness and safety of HA-SHA vs. a no-treatment control for augmentation and correction of chin retrusion.

Introduction: A new hyaluronic acid (HA) injectable, Restylane® ShaypeTM (HA-SHA; Galderma), has been developed using the new NASHA-HD™ technology, with improved efficiency to the cross-linking, creating a gel with high HA concentration (25 mg/mL), high G’ (916 Pa), and high gel content and stability. The product is to be injected on bone, aiming for an aesthetic improvement of chin retrusion that mimics the natural shape of the bony chin. A pivotal clinical investigation was conducted to assess effectiveness and safety of HA-SHA vs. a no-treatment control for augmentation and correction of chin retrusion.

Materials / method: Adults >18 years with mild or moderate chin retrusion on the Galderma Chin Retrusion Scale (GCRS) were randomized 3:1 to HA-SHA (n=103) or no-treatment control (n=37). The HA-SHA group received up to 4 mL HA-SHA on Day 1, and optional touch-up (up to 2 mL) at Month 1 if required for optimal results. Primary endpoint was the responder rate (≥1-grade improvement on the GCRS) at Month 3 as per the Blinded Evaluator live assessment. Other assessments included GCRS, aesthetic improvement on the Global Aesthetic Improvement Scale (GAIS), subject satisfaction, and adverse events (AEs) up to Month 12.

Results: After injection of a mean volume of 2.8 mL (≥95% supraperiosteally), the HA-SHA group had a significantly higher responder rate (83.3%) vs. controls (10.8%) at Month 3 (p<0.001). A high GCRS response was sustained throughout the study (74% and 66% in Months 9 & 12). Aesthetic improvement (GAIS) was achieved in ≥97% (by investigator) and ≥89% (by subject) from Month 1-12. The HA-SHA group subjects were satisfied with their chin shape (≥87%), projection (≥87%), and profile (≥82%) from Month 3-12. Product-related AEs were mostly mild to moderate, and non-serious (pain, tenderness, redness, etc.).

Conclusion: HA-SHA, a new NASHA-HD injectable, with high G’ and high HA concentration, significantly improves chin retrusion, compared with a no-treatment control. HA-SHA was effective for chin augmentation and correction of mild to moderate chin retrusion, with high aesthetic improvement and subject satisfaction sustained through Month 12. HA-SHA treatment had a good safety profile and was well tolerated throughout the 12-month study period.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): Investigator fees were paid from the study sponsor, Galderma.

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): Paid consultant, speaker, and clinical trial investigator for Galderma, Allergan, Prollenium and Merz

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Galderma

A Snapshot in Time – Experts’ Main Concerns on Adverse Event Prevention and Management in Aesthetic Treatments with Hyaluronic Acid Fillers (Sponsored by GALDERMA)

Objectives: To identify and prioritize topics or concerns related to adverse event management and prevention, for injectable fillers.

Introduction: Aesthetic practitioners prioritize preventing and managing complications associated with hyaluronic acid (HA) fillers and biostimulators; however, numerous aspects within the safety field remain controversial and despite guidance in the literature conflicting data exist. Galderma convened a safety task force with globally recognized experts in filler safety. The first meeting in a planned series of meetings was held on June 17th 2023.

Materials / method: The meeting gathered 15 experts, each with a background in scientific research, extensive clinical experience, and membership in diverse safety associations or committees. The experts represented eight countries including Austria, Brazil, Canada, China, France, Netherlands, South Korea, and US. The group identified and prioritized eight critical concerns related to filler adverse event management and prevention.

Results: The top concerns were: vascular adverse event management, hyaluronidase protocols, ultrasound (preventive and complication management), cannula versus needle, endpoints (landmarks to identify vascular occlusion), aspiration, treatment options beyond enzymes, and intraluminal versus extraluminal origins of vascular occlusion. Furthermore, a majority supported use of aspiration and cannulas for safer injections although the topic remains controversial. Skin color, condition, and capillary refill were deemed the best endpoints for addressing vascular adverse events.

Conclusion: Top priorities were identified for future review, including management of vascular adverse events, hyaluronidase protocols, and ultrasound use, with delayed complications also a key concern. The experts provided valuable insights, identifying concerns within adverse event prevention and management. A need remains to assess the current state-of-the-art for each strategy related to adverse event prevention and management. Furthermore, the frequently overlooked delayed-onset complications were also deemed a high-priority topic for the next meeting.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): Galderma

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): Dr Nikolis is a paid consultant, speaker, and clinical trial investigator for Galderma, Allergan, Prollenium and Merz.

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Galderma

Efficacy and Safety of SAMiRNA AR68 on Male and Female Androgenetic Alopecia without loss of Androgen, A randomized, Double-Blind Clinical Trial (Sponsored by COSMERNA™ BY BIONEER)

Objectives: The aim of this study was to evaluate the effects of CosmeRNA (SAMiRNA AR68), the world first RNAi technology driven solution on improvement of Androgenetic Alopecia in men and women.

Introduction: Self-assembled micelle inhibitory RNA (SAMiRNA) is a new type of siRNA nanoparticle that does not result in innate immune stimulation. SAMiRNA spontaneously forms spherical nanoparticles without cationic lipids in an aqueous solution. Therefore, SAMiRNA may be an ideal solution to overcome the stability and an undesirable innate immune response of current siRNA in the product development for Androgenic Alopecia.

Materials / method: Clinical studies were performed in a randomized and double-blind manner with two different doses and frequencies. In the low-dose (0.5 mg/ml) clinical study, AR68 was applied three times per week for 24 weeks, and through quantitative analysis using a phototrichogram, we confirmed increases in total hair counts.

Results: In the 24-week long high-dose (5 mg/ml) clinical study, AR68 showed average additional hair growth of 1.3-1.9 hairs/cm2 per month. No side effects were observed. Therefore, SAMiRNA targeting AR mRNA is a potential novel topical material for AGA.

Conclusion: This study demonstrates the efficacy and safety of
SAMiRNA-AR68 through an in vitro analysis of SAMiRNA-AR68 and two clinical studies. In comparison to the -9.3 hairs/cm2 average hair growth seen with daily oral administration of 1 mg finasteride over a 24-week period, high-dose AR68 application per week over 16-week period led to average hair growth of 7.5 hairs/cm2, indicating comparable efficacy as finasteride. AR68 has no side effects and is more convenient as a weekly application.
This study has limitations in a number of subjects and a spectrum of races.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No
Please specify entities (individual, company, society): COSMERNA ARI

Were you provided with any honoraria, payment or other compensation for your work on this study?
No
Please specify entities (individual, company, society): COSMERNA ARI

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): I am an investigator and CEO of Bioneer Corp.

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
Yes
Please specify date...: Registered
and status : June 04, 2020

This work is presented thanks to the support of: Bioneer Corp.

7 days after PDLLA(AestheFill) injection (Sponsored by AESTHEFILL® BY CHAEUM PHARMA)

Objectives: To show the collagen stimulation begins after 7 days of application of PDLLA

Introduction: Biostimulators are the latest trends in Cosmetic procedures, substances such as Poly-D, L-Lactic Acid are used to induce Collagen synthesis by a Sub clinical inflammatory reaction, however there are no data available showing the exact timing collagen stimulation begins after the application, in this report we want to show that Collagen production can be seen in biopsies samples after 7 days of the application of PDLLA.

Materials / method: A 34 year old female is our patient, a first biopsy was taken in the inner arm, this first biopsy is the basal sample or biopsy 0.
After the biopsy was taken, PDLLA (AestheFill®)was applied in the inner arm of the patient. PDLLA (AestheFill®)was diluted with 7cc of sterile water and lee of lidocaine without epinephrin, once AestheFill® was prepared and ready to use, PDLLA was applied with fanning technique all over the inner arm area. 7days after the application of AestheFill® another biopsy was taken in the same place it was applied. 2ldays after the application of AestheFill® another biopsy

Results: We chose 2 types of stainning for the biopsies; Hematoxylin and eosin Staining and the Masson Trichrome Stain. We could see twice the amount of fibroblasts compared to the basal biopsy, angiogenesis was also observed on the papillary dermis, lymphocytes, elastic fibers and collagen fibers were twice the amount compared to the basal biopsy. Another biopsy was taken 2ldays after the application and major histological changes were observed with an increasing amount of collagen fibers, elastic fibers as well as angiogenesis.

Conclusion: In this report we can observe that major histological changes in Collagen production are seen as early as 7 days after the application.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): AESTHEFILL® BY CHAEUM PHARMA

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): AESTHEFILL® BY CHAEUM PHARMA

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): AESTHEFILL® BY CHAEUM PHARMA

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: AESTHEFILL® BY CHAEUM PHARMA

An Economic Model for a Recently Introduced Ready-to-Use Liquid Formulation of AbobotulinumtoxinA (Sponsored by GALDERMA)

Objectives: The first ready-to-use (RTU) liquid formulation of abobotulinumtoxinA (aboBoNT-A solution) was introduced in Europe in 2021 for glabellar line treatment. To evaluate the impact on patient satisfaction and revenue for clinics switching from powder BoNT-A to the new RTU aboBoNT-A solution, a dynamic budget impact model was created, investigating clinical, logistic and economic aspects of this transition.

Introduction: Performance data on aboBoNT-A solution was available from 2 Ph3 clinical trials, 1 Ph4 study of usability and patient satisfaction, and 1 real-world study.

Materials / method: The dynamic economic model was built to assess the potential impact of using RTU aboBoNT-A versus powder BoNT-A on business revenue using variables to cover clinical (eg effect duration), safety (eg reconstitution errors), logistic (eg appointment frequency), economic (eg price) and commercial (eg patient acquisition) aspects. Model input included performance data from prior clinical and real-world studies, as well as data from a literature search validated by primary market research with practicing clinicians from UK, to define current practice baseline.

Results: Main clinical benefits of switching to RTU-aboBoNT-A fed into the model were faster onset, longer duration of action (6 vs 4 months) and reduced touch-up appointment rate (2 vs 10%), motivating patients to pay a higher price. Reduced appointment frequency frees capacities in the clinic, while clinical benefits of the product attract additional patients. The economic model considers different potential adoption rates of the product by the clinic, variable pricing scenarios and availability of additional capacities. The expected increase in revenue for the clinic ranged from £21000-195 000/year.

Conclusion: RTU-aboBoNT-A offers several clinical benefits positioning the product as a “Premium Product”, resulting in a greater willingness to pay an above-average price. Sharing of positive experience is expected to attract additional patients, taking up capacities freed by reduced required appointment rates. The model flexibly predicts increases in revenue depending on parameters that can be variably selected to reflect each clinic’s settings and preferences. Depending on selected parameters, increased revenues up to £195 000 per year are expected, for a 1 000 patient annual caseload.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): I am an employee of Galderma

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): I am an employee of Galderma

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Galderma

Overview of stability and extrudability of Hyal-System injectable line (Sponsored by FIDIA FARMACEUTICI)

Objectives: Hyal-System Line consists of five different hyaluronic acid based injectables products, all with variable characteristics.
They are obtained with linear and/or cross-linked HA and prepared with specific patented technologies.

Results: Stability
• Hyal-System injectable products display a variable resistance to degradation, due to the different hyaluronan concentrations and structures, ranging from linear to auto and BDDE-crosslinked hydrogels.

• Degradation kinetics were evaluated with an oxidative degradation assay and followed by rheological measurements.

• Kinetics constants and half-lives were determined and correlated with a physicochemical parameter ([HA] x elasticity %) that predicts the in vivo stability of the products.(2

Extrudability
• Extrusion force measurements allowed to characterize the range of extrudabi

Conclusion: The use of specific patented technologies allows to obtain a line of HA-based injectables with tunable features in terms
of residence time, degradation and extrudability designed to meet well-defined clinical expectations.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): FIDIA FARMACEUTICI

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): FIDIA FARMACEUTICI

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): FIDIA FARMACEUTICI

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: FIDIA FARMACEUTICI

Evaluating the Adjunctive Effects of Tranexamic Acid and Nicotinamide Containing Sunscreen in Chinese Subjects with Facial Hyperpigmentation Status. (Sponsored by L'ORéAL DERMATOLOGICAL BEAUTY)

Objectives: Thisstudy aimed to evaluate the efficacy and tolerance of AB UV for facial hyperpigmentation compared with a skin discoloration serum.

Introduction: Discoloration,
primarily characterized by skin unevenness and
dark spots 1 plays a critical role in perceptions of age, beauty,
allure, and overall health Skin color management is commonly
achieved by ingredients that target the biological process of
melanin synthesis and distribution 2 AB UV containing broad
spectrum UV filters, is also enriched with anti melanogenic
ingredients including niacinamide, tranexamic acid and Vitamin E
Niacinamide has proven efficacy in diminishing
hyperpigmentation by inhibiting the transfer of melanin from
melanocytes to keratinocytes 3 Tranexamic acid can inhib

Materials / method: In
a 28 day, single center, split face non inferiority trial, 45
healthy Chinese females aged 30 60 years with facial
hyperpigmentation on both sides and graded 2 5 according to
the Skin Aging Atlas were recruited This clinical study was
approved by Independent Ethics Committee of Shanghai Weipu
Chemical Technology Service Co ..,Ltd (No 202302 JC 17 After
14 days of washout, subjects applied AB UV in the morning for
one side, and control sunscreen plus control discoloration serum
(containing Arbutin, Centella Asiatica and Hyaluronic Acid) twice
daily to the other side At day 14 and day 28 inst

Results: A
total of 42 Chinese females were included in the analyses The
mean ( of age were 46 33 0 86 years old
As
shown in Figure 1 and 2 AB UV showed non inferiority than
the control brightening serum in all indicators at day 28 p 0 05
Additionally, compared with control side at day 28 improvement
rate was found in AB UV treated side in MI 2 62 ITA
18 38 radiance 404 20 proportion of hyperpigmentation
area 10 42 mean melanin density 0 90
hyperpigmentation density 50 92 and hyperpigmentation
contrast 6 70

Conclusion: The
findings indicated that AB UV exhibited brightening effect in
reducing skin hyperpigmentation and improving skin radiance,
non inferior to the controlled discoloration serum and was also
well tolerated

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: L'ORéAL DERMATOLOGICAL BEAUTY

Screw Caps: A Break with The Past (Sponsored by ALTHENA MEDICAL)

Objectives: Our goal was to develop and produce a screw cap easy to unscrew, even for a doctor wearing gloves, a screw cap that is suitable for sterilization in an autoclave and that guarantees a seal even years after ﬁlling the syringe.

Introduction: There is only one type of screw cap at present. This standard screw cap contains a rubber inside that wraps around the tip. In this way the doctor has to apply an initial force for unscrewing, which in some cases can be annoying. Our research comes from the complaints of doctors and specialists who, wearing gloves, find the current systems for unscrewing pre-filled syringes annoying and impractical. Our effort has been to find a different solution to the current standard: a simple, practical and easy to use solution.

Materials / method: The screw cap has been tested during autoclaving many times using various types of drugs and substances from ferroﬂuid materials, to bone cements, from hyaluronic acids with di erent densities to saline solutions. All the syringes, 100 pieces for every substance, were then subjected to hermeticity tests with blue methylene, thus demonstrating the absolute tightness of the cap.

Results: The same syringes have been subjected to fast aging, up to 5 years, proving also in this case the perfect seal of the cap. Tests with a torque wrench have shown that the necessary force to open one of our syringes is only 0.1 Nm, while standard syringes required 0.5 Nm.

Conclusion: Many laboratory tests have conﬁrmed that with a considerable reduction of the force torque when opening the syringe, the sealing power is remarkable and this is conﬁrmed both in the autoclave during sterilization and 3 years after ﬁlling the syringes.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): ALTHENA MEDICAL

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): ALTHENA MEDICAL

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): ALTHENA MEDICAL

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: ALTHENA MEDICAL

Evaluation of the anti-pigmenting efficacy of the association of vitamin B3, vitamin C and AHA in a topical serum, compared to the reference ingredient in the management of melasma. (Sponsored by L'ORéAL DERMATOLOGICAL BEAUTY)

Objectives: The management of melasma remains challenging Despite therapeutic options that act at different stages of melanogenesis, results are sometimes disappointing, and relapses are common For hydroquinone, the ingredient showing the most effective results, there is a concern regarding its tolerability and the possibility of prolonged use 1 4 The study aimed at evaluating the anti pigmenting efficacy of a topical serum (B 3 containing an association of 5 vitamin B 3 vitamin C and 8 AHA in the treatment of melasma for 5 months and its comparison with hydroquinone 4% (HQ 4)

Materials / method: The
study consisted of a prospective monocentric, double blind randomized trial,
including 65 women between 20 and 50 years old, of multiple ethnicities,
phototypes II to VI and presenting melasma for more than 1 year In the first 2
weeks of the study, subjects used face moisturizer and SPF 50 sunscreen daily
From the third week onwards, subjects were randomized into 2 groups One group
applied the B 3 serum daily in the morning and at night for 5 months The other
group applied HQ 4 at night for 3 months At the end of the 3 months, this group
stopped the treatment with HQ 4 and started the trea

Results: Reduction
in MASI score was observed after 3 months for both treatments 3 47 for
the B 3 serum and 3 71 for HQ 4 Reduction of the mMASI score was also similar for
both groups 1 97 for the B 3 serum and 2 05 for HQ 4 After replacing HQ 4 in the
third month, the efficacy was maintained and improved with the daily application
of the B 3 serum at the end of the 5 months 5 68 for MASI and 3 31 for mMASI [full
treatment with the B 3 serum] and 5 38 for MASI and 2 81 for mMASI [HQ 4 3
months and B 3 serum 2 months]) This corresponds to more than 40 decrease in
the MASI score in the 2 groups after 5 m

Conclusion: The serum containing combination of 5 vitamin B 3 vitamin C and 8 AHA demonstrated superior results in tolerance and erythema assessment after 1 month when compared to Hydroquinone 4 suggesting a better compliance to the treatment Both treatments showed, after 3 months, a parity in melasma improvement based on MASI and mMASI assessment and confocal microscopy methodology, with no statistical difference, ie the B 3 serum is a safe and efficacious alternative for melasma management in monotherapy and/or as an adjuvant.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: L'ORéAL DERMATOLOGICAL BEAUTY

Enhancing Skin Quality: HA-based RHA1 treatment followed by skin redensification with R1– A prospective, multicenter, interventional study Status (Sponsored by TEOXANE LABORATORIES)

Objectives: Skin quality plays a vital role in how age, attractiveness, health, and youth are perceived.1-4

• The smile is recognized as a central facial feature associated with youth and attractiveness.5

• Smiling lines in the cheek (or “accordion lines”) can arise from habitual smiling, extending from the periorbital area to the masseter region. 6-7

• Thus, addressing aesthetic concerns in the cheek area, including fine lines and skin quality, is crucial in improving overall beauty perception.

Materials / method: SKINQARE (NCT05349799)10: a prospective, low-interventional, multicentre, open-label study to assess the performance and safety of skin beautification treatment with RHA1 for fine lines (e.g., smiling lines) (Figure 1) including an exploratory arm in which subjects treated with RHA1 received multiple sessions of R1 injections to assess skin redensification.

Conclusion: ✓ RHA1 was effective and safe for the aesthetic enhancement of smiling lines.

✓ Successive dermal or subcutaneous treatments with R1 following RHA1, using a needle or a cannula, showed further improvement when compared to RHA 1 used alone, which was correlated with skin quality measurements (i.e., further improvement in wrinkle thickness and fractional area after RHA1+R1 treatment).

✓ Subject assessment is a key element to properly evaluate treatment efficacy by considering additional benefits which might not be assessed through scales.

✓ Subjects mainly found their skin hydrated, firm and

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): TEOXANE LABORATORIES

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): TEOXANE LABORATORIES

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): TEOXANE LABORATORIES

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: TEOXANE LABORATORIES

DISCOVERY OF 2-MERCAPTONICOTINOYL GLYCINE (Sponsored by L'ORéAL DERMATOLOGICAL BEAUTY)

Objectives: Melanin production inhibitors currently marketed inhibit tyrosinase, the rate limiting enzyme in melanin synthesis process. Yet only a few have demonstrated clinical efficacy while some present safety issues. Moreover, environmental respect is barely taken into consideration. Research on skin lightening agents considering efficacy. safety but also environmental respect is then of great importance to significantly improve marketed actives.

Introduction: For this purpose, a high throughput screening test (HTS) evaluating melanin production on a large chemical diversity and in silico predictive methodology was then used to design original and performant chemical structures resulting in the discovery of 2-mercapto nicotinoyl glycine (2-MNG). Mechanism studies were conducted in tubo, in vitro, as well as in vivo showing a unique model of action of 2-MNG consisting in conjugating with melanin precursors, avoiding their integration into growing eumelanin and pheomelanin.

Materials / method: In vitro screening and 2-MNG discovery:
HTS assay: Normal human melanocytes (NHM) were cultivated in 384-well plates. Over 100 000 raw materials were screened after dilution in the culture medium at 10 doses and incubation for 72 hours. Optical density was measured at 340 m reflecting melanin content. Data was normalized in comparison with untreated cells. IC 50 was determined.
Environmental profile assessment & in silico prediction: Water footprint index (WFI) was determined. An internal digital tool was used to design and screen the best thiopyridinone profiles, taking into consideration p

Results: Selection of 2-MNG: HTS screening led to the discovery of thiopyridinone chemical family as potent brightening structures. 197 analogs were virtually designed and screened based on in silico prediction of relevant parameters' (safety, environmental respect, skin penetration). 2-MNG (WFI=11) was selected for further investigation as displaying the best compromise between these parameters
and WFI compared to on-market benches: 4-n-BR WFI = 5813, kojic acid WFI= 316 (Figure 1).

Conclusion: 2-MNG is a new molecule displaying a high efficacy in managing melanin production in vitro. Its mode of action, which consists of binding and thus inactivating melanin precursors, leads to a high clinical performance either on prevention of skin darkening or inhibition of delayed tanning with no adverse effects

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: L'ORéAL DERMATOLOGICAL BEAUTY

Clinical Evaluation of the Moisturizing, Reduce Redness and Oil-Control Effects of a Lotion Containing Azelaic Acid, Alpha-Arbutin with Botanical Ingredients on Sensitive Oily to Combination Skin (Sponsored by L'ORéAL DERMATOLOGICAL BEAUTY)

Objectives: To evaluate the moisturizing, reduce redness and oil control effects of a lotion containing Azelaic Acid, Alpha arbutin with Botanical Ingredients on sensitive oily to combination skin

Introduction: Sensitive
skin exhibits a variety of clinical signs and symptoms, including edema,
erythema, facial flush, pruritus, burning, pain, and stinging 1 Azelaic acid has
profound anti inflammatory, anti oxidative effects 2 Arbutin could be beneficial
in treatment of hyperpigmentation disorders 3 Botanical Ingredients could inhibit
cytokines, which are associated with erythema, edema, skin pain, and pruritus 4
This study aimed to prospectively evaluate the moisturizing, reduce redness and
oil control effects of a lotion containing Azelaic acid, Alpha arbutin with
Botanical ingredients on sensitive oi

Materials / method: A
prospective, randomized, split face, controlled trial was
conducted with 42 Chinese female subjects with sensitive oily to
combination skin aged 18 45 years with a lactic acid tingling
score 3 One side of the face was randomized to receive a lotion
containing Azelaic Acid, Alpha arbutin with Botanical
Ingredients (test product) and the other side to receive glycerin
cream (control product) One application was made every
morning and evening for 28 days Erythema index, trans
epidermal water loss ( skin oil content and skin
glossiness were detected at baseline, day 7 day 14 and day 28
after usi

Results: Compared
to the control product treated sides, there was a significant decreases in erythema index, TEWL, skin oil content and significant increase in skin
glossiness on the test product treated sides at day 7 day 14 and day 28 Compared to baseline, the decrease rates of erythema index, TEWL and skin oil
content were 14 29 21 82 and 35 87 respectively, and the increase rate of skin glossiness was 24 80 on the test product treated sides at day 28

Conclusion: The test lotion has moisturizing, reduce redness and oil control effects on sensitive oily to combination skin

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: L'ORéAL DERMATOLOGICAL BEAUTY

The world's first device that stops hair loss and promotes its regrowth (Sponsored by APS SRL)

Objectives: Evaluation of the efficacy and tolerability of a combined therapy: preformed growth factors vehiculated through iontophoresis in patients with androgenetic alopecia and associated telogen efflu- vium, to obtain faster hair regrowth.

Introduction: Hair loss represents a problem for the patient for cos- metic and psychological reasons because hair sym- bolizes an important mirror of our image and a physical attractiveness to self-perception of beauty. The field of hair disorders is constantly growing. The first step to address this issue, is to collect a good historical record and perform a thorough physical examination. Labo- ratory testing is often unnecessary, while trichoscopy is fundamental for all hair diseases. Androgenetic al- opecia and telogen effluvium are common causes of non-scarring alopecia. Many treatments are available,

Materials / method: Treatment was performed between June 2018 and June 2019 on 60 pa- tients with androgenetic alopecia and associated telogen effluvium. Each patient underwent 4 sessions in total, each session was performed every 3 weeks. Global photography and trichoscopy were collected at every session of therapy. All patients filed out a self-assessment questionnaire.

Results: Results were very promising, with improvement of hair density and thickening of the hair shaft diameter in most of patients seen with both global photography and trichoscopy. All patients were satisfied of the clinical result and reported a complete reduction in hair loss. No serious adverse side effects were reported.

Conclusion: The use of growth factors associated with iontophoresis technique is a useful treatment for treating and preventing androgenetic alopecia. In addition, in case of associated telogen effluvium, this technique allows for an early stop of hair shedding, especially when cosmetic procedures do not provide satisfactory results in patients.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): APS SRL

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): APS SRL

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): APS SRL

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: APS SRL

Scar Management with Finexel (Sponsored by SNJ)

Objectives: A scar is a connective tissue formed in the healing process at the site of the traumatic action. Scars can be divided into mature and immature scars, and due to their shape into linear, atrophic, hypertrophic and keloids [l]. Another classification is to take into account the causative factor, and thus scars can be divided into postoperative, post-traumatic, including burns, and inflammatory scars [2]. Care for a burn wound and the prevention of contractures and burn scars are beyond the scope of this study.

Introduction: The quality and appearance of the scar depend on many factors, including endogenous factors (e.g. cachexia, skin laxity, nicotinism) and exogenous factors (e.g. infections, localization, surgeon's skills). The treatment of the scar should begin at the stage of planning the surgical incision and selecting the suture material (primary prophylaxis). The use of the Langer line, ie the line of reduced tension, is a very important aspect of obtaining the best aesthetically pleasing scar [3]. Placing sutures in order to bring a wound closer, also a traumatic wound, should be performed without tens

Results: Lasers distribute energy, leaving numerous microscopic treatment zones {MTZ) on the skin, which initiate the process of tissue reconstruction and regeneration[S].

Conclusion: Finexel - is a modern medical ablation CO2 laser, the unique parameters of which allow for deeper penetration into the skin and a shorter healing period. The laser can be used in the surgical mode as well as in the fractional mode for aesthetic medicine procedures. The laser has an advanced laser source, offering remarkable treatment precision, thanks to the 80um spot diameter and the UltraPulse mode with high peak power. It is equipped with a fast scanner, offering the largest treatment area available on the Polish market, for the maximum reduction of treatment time. It has a friendly men

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): SNJ

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): SNJ

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): SNJ

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: SNJ

Physicochemical properties of two poly L-lactic acid dermal fillers: potential impact on their biological properties (Sponsored by GALDERMA)

Objectives: To evaluate the thermal properties and crystallinity of two commercially available poly L-lactic acid (PLLA) dermal fillers, Sculptra® (PLLA-SCA; Galderma, Sweden) and GANA V® (PLLA-GA; GCS Co., Seoul, South Korea), and how these properties might affect the subclinical inflammatory response that stimulates collagen growth in the skin.

Introduction: Dermal fillers have been used for many years in cosmetic dermatology. Across all PLLA fillers currently available, PLLA-SCA is the most widely studied. PLLA fillers comprise a mixture of PLLA microparticles and other components and, despite similar formulations, differences are often observed in their clinical application in daily practice. Moreover, degradation of PLLA is dependent on factors such as stereochemistry, molecular weight, crystallinity, particle size and microparticle morphology. Hence, the physicochemical characteristics of a PLLA filler can influence its clinical performance.

Materials / method: The thermal properties and the degree of crystallinity of PLLA-SCA and PLLA-GA were determined using differential scanning calorimetry analysis. Samples were scanned from 25 to 300°C in a nitrogen atmosphere with a heating rate of 10°C/min. Additional samples were heated to 120°C, allowed to cool to room temperature and then analysed by heating from 25 to 300°C at a heating rate of 10°C/min. PLLA-SCA and PLLA-GA samples were also analysed using an X-ray powder diffractometer. Measurements were performed at room temperature (approximately 22°C).

Results: The X-ray powder diffraction spectra displayed a sharper and more intense peak for PLLA-GA compared with PLLA-SCA. There were also additional smaller peaks on either side of the main peak in the diffractogram of PLLA-GA that were absent with PLLA-SCA. The differential scanning calorimetry thermograms indicated that there were three thermal events occurring for both the PLLA-SCA and PLLA-GA samples. For PLLA-SCA, the first two thermal events occurred between 65 and 90°C and the third thermal event occurred at 165°C, while for PLLA-GA all three thermal events occurred between 156°C and 169°C.

Conclusion: PLLA-GA has a more crystalline structure than PLLA-SCA, and the three melting points of PLLA-GA suggest it comprises a heterogeneous mix of polymer isoforms. The single melting point observed with PLLA-SCA suggests the presence of a homogenous formulation of PLLA-SCA which, combined with the less crystalline structure, could result in a slower degradation rate and more sustained biological response versus PLLA-GA. Degradation rate may impact treatment duration and could, in part, explain the 24-month duration of effect observed with PLLA-SCA in pivotal clinical trials.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No
Please specify entities (individual, company, society): GALDERMA

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): Honorarium was paid by Galderma.

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No
Please specify entities (individual, company, society): GALDERMA

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Galderma

POST-COMBAT BURNS AND SCARS TREATMENT: UKRANIAN EXPERIENCE (Sponsored by BIOFORMULA)

Objectives: Following the Russian invasion of Ukraine on February 24, 2022, a significant number of civilians and military personnel were affected, many experiencing combined thermo-mechanical type injuries.
To address this urgent problem, the 'Un-burned' humanitarian project was initiated in July 2022 (www.neopalymi.in.ua).
It brought together 25 clinics specializing in aesthetic medicine and cosmetic der-matology, where doctors volunteered their expertise, leveraging their extensive know-edge and experience in skin restoration and working with postoperative scars.

Introduction: Various methods have been proposed for the treatment of scars; however, many of them lack clear randomized controlled clinical studies to validate their effectiveness. Additionally, there is often a lack of appropriate labeling or classification of scars, which hinders the ability to determine optimal treatment approaches. It is important to note that the scar changes over time, and improvements may not necessarily be attributed to the treatment itself, but rather to the natural maturation process of the scar. The sequence of tissue repair following injury is tightly regulated to achieve optim

Materials / method: In our Project, a total of 125 patients are undergoing treat-
ment at various stages.
For this report, we focused on evaluating the preliminary results of rehabilitation treatment in 57 patients. Both doctors and patients assessed the outcomes using the POSAS scale before treatment, after the injection + IPL stage, and after the second resurfacing stage. The evaluation included indicators such as pigmentation, erythema (vascularization), elasticity, tension, and the contrast between healthy skin and scar tissue. Patient assessment also considered factors like un-evenness, hardness, tenderness,

Conclusion: Post-combat scars commonly exhibit a combination of atrophic, hypotrophic, and hypertrophic skin changes. These scars often display noticeable areas of both hypopigmentation and hyperpigmentation, along with tissue hypervascularization
The development of modern treatment protocols should aim to achieve the following objectives: reducing inflammation duration, normalizing angiogenesis and reducing excessive capillary forma-tion, enhancing elasticity by influencing collagen formation and normalizing caveolin metabolism by introducing the drug PDRN into affected tissues (in our case Plenhyage XL

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): Bioformula have support with medications

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Bioformula

A randomized, comparative study describing the gene signatures of Poly-L-Lactic Acid (PLLA-SCA) and Calcium Hydroxylapaptite (CaHA) in the treatment of nasolabial folds (Sponsored by GALDERMA)

Objectives: To identify and compare gene signatures of skin biology-related genes 3 months after initial treatment with injectable poly-L-lactic acid (PLLA-SCA) and calcium hydroxylapatite (CaHA) via punch biopsies of the nasolabial folds (NLF) and to assess volume change in the NLF with 3D photography.

Introduction: PLLA-SCA, a biostimulator, and CaHA, a biostimulatory filler, have been shown to stimulate varying ratios of type 1 and type 3 collagen. The gene signatures related to skin biology for each collagen biostimulatory agents are unknown. 

Materials / method: This was a single-center, randomized, comparative study in which subjects with a minimum of shallow NLF received 2 treatments of on-label PLLA-SCA injections or CaHA injections at a 4-week interval for optimal correction. Study assessments included punch biopsies and 3D photography at Baseline and 3 months post first treatment.

Results: Eleven subjects received PLLA-SCA and ten subjects received CaHA. Both treatments induced gene expression associated with collagen formation, inflammation, and extracellular matrix remodeling. Compared to CaHA, PLLA-SCA quantitatively expressed more genes related to regeneration and morphogenesis (16% vs 10%), and less genes related to inflammation (14% vs 18%) and pro-inflammation (5% vs 11%) at 3 months. 3D photography demonstrated improvement in depth and volume, in line with previously published data on NLF correction. There were no treatment-related adverse events throughout the study.

Conclusion: This study suggests that PLLA-SCA and CaHA have differentially expressed gene signatures and unique mechanisms of action. PLLA-SCA upregulated more genes relating to regeneration and morphogenesis, whereas CaHA was more inflammatory and pro-inflammatory.  

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): GALDERMA

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): GALDERMA

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): GALDERMA

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: GALDERMA

A TOPICAL FORMULA CONTAINING PROXYLANE AND NIACINAMIDE AUGMENTS THE ANTI-AGEING BENEFITS OF A NON-ABLATIVE LASER TREATMENT (Sponsored by L'ORéAL DERMATOLOGICAL BEAUTY)

Objectives: The objective of this study was to demonstrate the mechanism of action and the clinical efficacy in enhancing the benefits of aesthetic procedures by pairing PX/NAM with non-ablative fractional laser procedure.

Introduction: Minimally invasive aesthetic procedures, such as microneedling and
non-ablative laser treatment, are rapidly increasing in popularity
due to minimal recovery and downtime with effective results for
skin rejuvenation.1-3 Those procedures induce microwounds in a well
controlled way in the dermis or epidermis that activate a woundhealing
cascade, skin regeneration, and enhanced permeability of
active components in post-procedure skincare products.4, 5.
Despite the advancement in minimally invasive aesthetic procedures,
post-procedure care options are limited to lower the downtime and
augment the

Materials / method: In vitro testing
The mechanism of action of PX and NAM was elucidated using in tubo assays, 2-D melanocyte and fibroblast cultures,
reconstructed skin equivalents and human ex vivo skin explants.
Clinical evaluation
• Randomized, double-blind, split-face, benchmark-controlled multi-center study in complement to non-ablative fractional
laser procedure.
• Included were 37 females (25 Hispanic Caucasian and 12 Northeaster Asian women from China, Korea and Japan), 30-65 years
of age with Fitzpatrick skin type II-III or II-IV with non-sensitive skin who presented with mild to severe crow’s feet wri

Results: In vitro testing
• PX/NAM encouraged alpha-Smooth Muscle Actin production, an indicator for
wound contraction
• In vitro testing suggested complementary mechanism of action between PX and
NAM for a post-procedure setting.
• PX enhanced the level of soluble Glycosaminoglycan production while
NAM encouraged cell migration and decreased both inflammation and
inflammation-associated melanin production (Figure 1).
• PX/NAM augmented barrier renewal following microneedling. Changes in
morphology demonstrated improved epidermal differentiation and renewal (Figure 2).

Conclusion: This study elucidates that the pairing of PX/NAM benefits post-procedure skin by enhancing the level of barrier renewal and reducing the level of inflammation and melanogenesis. These benefits translated to the creation of a topical formula that augments the anti-ageing benefits of non-ablative laser procedure at a superior level when compared to PBO.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: L'ORéAL DERMATOLOGICAL BEAUTY

Clinical Evaluation of Two Topical Products Containing Blueberry, Purple Rice Extract and Pro-xylane in Combination in Chinese Females with Mild-to-Moderate Facial Aging_(Sponsored by L'ORéAL DERMATOLOGICAL BEAUTY)

Objectives: To evaluate the efficacy and satisfaction of two topical products containing blueberry extract, purple rice extract and pro xylane (test product) for improving.

Introduction: Facial
aging has caused serious troubles to patients’ lives which is characterized by fine lines around the eyes, mouth, cheeks, skin laxity
and lack of elasticity 1 With aging, the number of advanced glycation end products ( increases, affecting every cell type in the body
The pathological effects of AGEs include increasing vascular permeability, inhibiting vasodilatation by interfering with nitric oxide, oxidizing
LDL and inducing cytokine secretion 2 All these factors increase oxidative stress and thus promote aging Blueberry extract can inhibit the
production of AGEs Pro xylane may mediate

Materials / method: A prospective, randomized split face, controlled trial was conducted with 49 Chinese female participants with mild to moderate facial aging aged 25 55 years One side of the face was randomized to receive test product and the other side to be treated with control product, twice daily for 12 weeks Stratum corneum water content, Transepidermal water loss ( Skin elasticity (R 5 Skin tightness (R 3 were detected on both sides at baseline, day 14 day 28 day 56 and day 84 Clinical assessments of wrinkles by physicians and participants’ satisfaction questionnaire were also collected.

Results: Compared to control side, test product treated side showed better improvement in Stratum corneum water content TEWL, Skin elasticity (R 5 and Skin tightness (R 3 at day 14 day 28 day 56 and day 84 Compared to baseline, the increase rates of Stratum corneum water content and Skin elasticity (R 5 were 74 81 45 24 respectively, and the decrease rate of TEWL and Skin tightness (R 3 were 20 20 27 03 respectively on the test product treated sides at day 84 Compared to baseline, Clinical assessments values of wrinkles around the corners of the eyes, under the eyes, around the corners of the mouth and

Conclusion: Application of the combination of two topical products containing blueberry extract, purple rice extract and pro xylane is an effective method for improving facial aging in Chinese population.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: L'ORéAL DERMATOLOGICAL BEAUTY

Tissue changes over time after polydioxanone thread insertion: An animal study with pigs (Sponsored by N-FINDERS)

Objectives: We aimed to determine what significant changes occur in the tissue over time when a PDQ suture is inserted.

Introduction: In early 2011, a treatment using monofilament polydioxanone (PDQ) thread for facial rejuvenation was introduced in Korea. Absorbent threads used for lifting are divided into monofilament type threads without teeth and barbed threads with teeth. Clinical studies using PDQ threads have shown positive results. Suh and colleagues demonstrated that monofilament treatment can improve tightening and skin texture, indicating that PDQ thread injection can induce positive changes in facial tissue.

Materials / method: Four white Yucatan breed pygmy pigs with skin most similar to human skin structure were selected. 4-0 PDQ thread was inserted into the subcutaneous fat layer. Tissue samples were collected at 4, 12, 24, and 48 weeks. For histological analysis, H&E staining, Masson's trichrome staining, and anti-smooth muscle actin immunohistochemical staining techniques were used.

Results: Nine histological findings emerged over time, summarized in five tissue changes.

Conclusion: PDQ suture causes specific changes in the surrounding tissue, resulting in nee-collagen production, fiber fusion effect, fat reduction, tissue construction, and improved vascular environment. The results of this study explain the positive changes described in previous clinical studies.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): N-FINDERS

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): N-FINDERS

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): N-FINDERS

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: N-FINDERS

Novel Pathway in Enhancing Patient Comfort Post-Procedure with a Topical Treatment (Sponsored by REVISION SKINCARE)

Objectives: I. To develop a post-procedure cream (PPC) that can immediately be used by patients after receiving an energy-based treatment to ameliorate discomfort and promote healing for enhanced recovery and increased likelihood patients will complete the recommended treatment series.

II. To determine the effect of the PPC in modulating the transient receptor potential vanilloid 1 (TRPV1) and stimulating the production of beta-endorphins after skin explant procedure treatment with thermal and mechanical energy.

Introduction: Skin rejuvenation procedures include those that wound skin through mechanical means, through chemical aggressors, and through the use of energy-based devices to treat aging facial skin concerns. These three common types of skin rejuvenation procedures vary in intensity, depth of penetration into the skin, and patient post-procedural downtime. Even though the end result from these rejuvenation procedures are notable and desirable, the negative experience of these procedures reduces the likelihood that the patient will return to complete the optimal series of treatments.

Materials / method: A semi-occlusive, breathable post-procedure cream (PPC) was formulated with botanical ingredients that directly stimulate communication between the nervous system and the skin. The PPC is a reverse emulsion (water-in-oil) which allows for effective delivery of water-soluble ingredients to a disrupted skin barrier by the action of a lipophilic base. Skin from plastic surgery of 48-year-old Caucasian women with Fitzpatrick Skin Type II was irradiated with UVB at 0.5 J/cm2 followed by microneedling. PPC was applied to the skin post-procedure for 3 hours and TRPV1 and beta endorphin were measured.

Results: Compared to skin explants damaged by UVB radiation and microneedling, there was a progressive decrease in TRPV1 expression and an increase in beta-endorphin expression when skin explants were treated with the PPC post-procedure. After 3 hours of treatment (post procedure), a highly statistically significant increase in beta endorphin of 104.9% was determined (*** p < 0.001). Conversely, a highly statistically significant decrease in TRPV1 by 54.8% was determined (*** p < 0.001).

Conclusion: The developed PPC targets an unmet need in post-skin rejuvenation procedures to improve post-procedure discomfort, enhance recovery time, and increase patient treatment plan adherence. This semi-occlusive, breathable cream formulated with neurocosmetics, microbiome technology, and hydrators and without anesthetics, can be applied to skin immediately after chemical, mechanical, and thermal based treatments. Results from the ex vivo study demonstrated the PPC targets specific biological pathways to reduce discomfort by suppressing TRPV1 while increasing the local production of beta endorphins.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): REVISION SKINCARE®

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
Yes
Please specify date...: Patent-Pending
and status : Patent filing date March 2022

This work is presented thanks to the support of: Revision Skincare

Clinical Evaluation of a Topical Antioxidant Serum Containing Resveratrol, Baicalin, and Vitamin E in Photodamaged Facial Skin. (Sponsored by L'ORéAL DERMATOLOGICAL BEAUTY)

Objectives: This study aimed to evaluate the efficacy of Resveratrol BE for mild to moderate photodamaged facial skin to improve signs of skin aging, including fine lines, winkles, elasticity, firmness, roughness and radiance

Introduction: Skin
aging is an intricate biological process composing both
intrinsic and extrinsic factors 2 Aged skin is mainly
characterized by the appearance of wrinkles and the reduction
of skin firmness Skin deterioration involves various
mechanisms, among which, the generation of ROS playing a
significant role in both extrinsic and intrinsic aging process 3
The
antioxidant capacity of resveratrol, baicalin and Vitamin E,
which are active ingredients of Resveratrol BE, have been
confirmed 1 Resveratrol, in particular, functions as a dual
antioxidant that can neutralize free radicals and increase
intrin

Materials / method: A
12 week, single center clinical study was conducted in 55
healthy Chinese females aged 30 60 years with mild to
moderate facial skin laxity, roughness, fine lines and wrinkles
After 7 days of washout, subjects applied Resveratrol BE to
their face at bedtime for 12 weeks Instrumental evaluation was
performed including winkles’ measurement (PRIMOS CR),
elasticity and firmness (Cutometer dual MPA 580 roughness
(VisioScan ® VC 20 plus) and radiance Glossymeter GL 200 at
baseline (before treatment) and at 2 4 8 and 12 week Efficacy
and tolerance were assessed by clinical grading and self
assessme

Results: A total of 50 Chinese females were included in the analyses. The mean ( age of the subjects was 47 22 1 03 years old.

Conclusion: This clinical study reveals that the nighttime topical antioxidant serum Resveratrol BE produced significant improvements in signs of facial skin aging Application of Resveratrol BE is an effective method for skin rejuvenation by repairing accumulated damage and preventing future aging

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): L'ORéAL DERMATOLOGICAL BEAUTY

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: L'ORéAL DERMATOLOGICAL BEAUTY

Speakers	Lecture title	Abstract	Number
Dr Arturo ALMEIDA	The principles behind AlidyaⓇ, the first injectable device ever designed to treat cellulite (Sponsored by MARLLOR BIOMEDICAL)	View	134825
Prof Roberto AMORE	Treatment of dimpling from cellulite. (Sponsored by LOVE COSMEDICAL)	View	133323
Prof Roberto AMORE	Skin reconditioning compound for anti-aging. (Sponsored by LOVE COSMEDICAL)	View	133325
Prof Roberto AMORE	Supraperiosteal Filling Technique for Full Face Rejuvenation. (Sponsored by LOVE COSMEDICAL)	View	133324
Dr Shino BAY AGUILERA	A review of Radiesse® as a regenerative aesthetic treatment (Sponsored by MERZ AESTHETICS)	View	134821
Dr Katie BELEZNAY	Safety and Effectiveness of Poly-L-lactic acid (PLLA-SCA) for the Improvement in Appearance of Cellulite – A Pilot Study (Sponsored by GALDERMA)	View	134945
Dr Carlo BORRIELLO	ReBorn 940nm IR Power LED Technological Breaktrough - A new source of energy for fat cells apoptosis (Sponsored by LIGHTFECTIVE)	View	134824
Dr Gregory W CHERNOFF	The Utilization of Human Placental Mesenchymal Stem Cell Derived Exosomes in Aging Skin: An Investigational Pilot Study (Sponsored by KIMERA LABS)		134746
Dr Zoe Diana DRAELOS	A multi-center trial evaluating a serum comprised of plant-based adaptogens targeting homeostasis and skin quality Status. (Sponsored by L'ORéAL DERMATOLOGICAL BEAUTY)	View	133320
Dr Zoe Diana DRAELOS	INTERNATIONAL CONSENSUS ON ANTI-AGING DERMOCOSMETICS AND SKINCARE FOR CLINICAL PRACTICE USING THE RAND/UCLA APPROPRIATENESS METHOD (Sponsored by L'OREAL DERMATOLOGICAL BEAUTY)	View	135542
Nadege DURAND	CLINICAL EFFICACY OF A NOVEL DAILY FACE CREAM, WITH A PATENT-BASED ACTIVE, ON THE KEY SIGNS OF AGING (Sponsored by LABORATOIRES FILORGA PARIS)	View	134874
Dr Refael EMILIO	Observation of the aesthetic effect of Hyaluronic acid lips filler. (Sponsored by LABORATORIES HYAMED SA)	View	134088
Dr Sabrina FABI	A multi-center, retrospective, chart review to evaluate the safety of poly-L-lactic acid injectable implant when used in non-facial areas (Sponsored by GALDERMA)	View	134946
Dr Ferial FANIAN	Effects of the combination of Ca-Hydroxyapatite with NCTF® 135HA on the fibroblasts’ contractile force and collagen and elastin induction (Sponsored by FILLMED LABORATOIRES)	View	134940
Dr Ferial FANIAN	Safety and longevity of Tri-Hyal® technology through comparative animal study and clinical trial. (Sponsored by FILLMED LABORATOIRES )	View	136401
Dr Ferial FANIAN	The effects of Tri-Hyal® technology on different skin layers using High resolutional imaging technology. (Sponsored by FILLMED LABORATOIRES )	View	136402
Dr Frederic FLAMENT	2-MERCAPTONICOTINOYL GLYCINE: A NEW MOLECULE THAT PREVENTS AND DECREASES UV-INDUCED PIGMENTATION (Sponsored by L'OREAL DERMATOLOGICAL BEAUTY)	View	134843
Dr Annalisa FORNI	Preclinical and Clinical Evaluation of ACTV8SKN Actuator on Enhancing Skin Renovation: Impact on Collagen and Elastin Expression and Skin Quality Parameters (Sponsored by CONTRAD SWISS SA)	View	135458
Dr Salvatore Piero FUNDARO	Skin Tissue Modification with two different types of needling and radiofrequency (Sponsored by CAMPOMATS)	View	134876
Dr Francine GERSTEIN	Efficacious with minimal side effects : A novel treatment regimen for acne vulgaris using multifunctional ingredients. (Sponsored by ALUMIERMD)	View	136399
Dr Michael H GOLD	Ph III efficacy and safety data on relabotulinumtoxinA, an investigational liquid botulinum toxin for treatment of glabellar or lateral canthal lines (Sponsored by GALDERMA)	View	134942
Dr Kate GOLDIE	The evolving field of regenerative aesthetics (Sponsored by MERZ AESTHETICS)	View	134877
Dr Alessandro GRITTI	An Evaluation of VYC-17.5L for Forehead Contouring: A Prospective, Open-Label, Post-Marketing Study (Sponsored by ALLERGAN AESTHETICS)	View	135591
Dr Alessandro GRITTI	A Prospective, Open-Label Post-Marketing Study of Safety and Effectiveness of Ha/CaHA Filler for Midface Soft Tissue Augmentation: Interim Analysis. (Sponsored by ALLERGAN AESTHETICS)	View	135594
Dr Alessandra HADDAD	Utilizing the AART methodology to maximize aesthetic treatment outcomes across different patient profiles (Sponsored by GALDERMA)	View	134947
Leticia HUERGO ZAPICO	Zionic rollactive massage and diathermy-based technology. Leads to adipose tissue reduction and contouring effect. (Sponsored by TERMOSALUD)	View	133273
Leticia HUERGO ZAPICO	Symmed, when versatility meets technology. (Sponsored by TERMOSALUD)	View	133274
Dr Javed HUSSAIN	Trichloroacetic acid based chemical peeling treatment of Fitzpatrick IV-VI skin phototypes: specifics and outcomes (Sponsored by SKIN TECH PHARMA GROUP)	View	136047
Dr Javed HUSSAIN	Efficacy study of novel monophasic dermal implant containing cross-linked hyaluronic acid associated with amino acids for treatment of hands photoaging (Sponsored by SKIN TECH PHARMA GROUP)	View	136048
Dr Yong Ho HWANG	Combination Treatment with Laser & Mask (Sponsored by SNJ)	View	135917
Dr Philippe KESTEMONT	Estyme® lips and Estyme® smooth, two Nnew HA dermal fillers for a global treatment of the lips and the perioral area. (Sponsored by SYMATESE)	View	136400
Dr Wooram KIM	The bidirectional cogged thread loaded into the specially designed flex-form cannula (Sponsored by AYOON MEDI)	View	134939
Dr Bianca LENCI VISCOMI	Retrospective case series following patients treated with a combination of CPM-HA and CaHA fillers (Sponsored by MERZ AESTHETICS)	View	134822
Dr David LUKANOVIC	The use of magnetic stimulation for the treatment of female urgency urinary incontinence (Sponsored by ISKRA MEDICAL)	View	135811
Dr Kay MARQUARDT	Attraction of fibroblasts by Micro-Focused Ultrasound (MFU-V) (Sponsored by MERZ AESTHETICS)	View	134878
Dr Tamara MARTINEZ VALVERDE	Pre clinical and clinical evaluation of lifting effect of the synergic association between biotechnological collagen and lupeol extract (Sponsored by MARTIDERM)	View	135460
Dr Alec MCCARTHY	Physical properties of diluted Radiesse® (Sponsored by MERZ AESTHETICS)	View	134823
Prof Mark Steven NESTOR	Evidence-based science behind the diffusion and spread of abobotulinumtoxinA (Sponsored by GALDERMA)	View	134944
Dr Andreas NIKOLIS	Effectiveness and Safety of a New NASHA-HD Hyaluronic Acid Injectable, HA-SHA, for Augmentation and Correction of Chin Retrusion (Sponsored by GALDERMA)	View	134950
Dr Andreas NIKOLIS	A Snapshot in Time – Experts’ Main Concerns on Adverse Event Prevention and Management in Aesthetic Treatments with Hyaluronic Acid Fillers (Sponsored by GALDERMA)	View	134951
Dr Han Oh PARK	Efficacy and Safety of SAMiRNA AR68 on Male and Female Androgenetic Alopecia without loss of Androgen, A randomized, Double-Blind Clinical Trial (Sponsored by COSMERNA™ BY BIONEER)	View	134826
Dr Kateryn Michelle PEREZ WILLIS	7 days after PDLLA(AestheFill) injection (Sponsored by AESTHEFILL® BY CHAEUM PHARMA)	View	134873
Cecilia PERSSON	An Economic Model for a Recently Introduced Ready-to-Use Liquid Formulation of AbobotulinumtoxinA (Sponsored by GALDERMA)	View	134943
Dr Stefano PLUDA	Overview of stability and extrudability of Hyal-System injectable line (Sponsored by FIDIA FARMACEUTICI)	View	135810
Dr Xiaolei QIN	Evaluating the Adjunctive Effects of Tranexamic Acid and Nicotinamide Containing Sunscreen in Chinese Subjects with Facial Hyperpigmentation Status. (Sponsored by L'ORéAL DERMATOLOGICAL BEAUTY)	View	133321
Alfredo RICCI	Screw Caps: A Break with The Past (Sponsored by ALTHENA MEDICAL)	View	134087
Dr Juliane ROCIO NEVES	Evaluation of the anti-pigmenting efficacy of the association of vitamin B3, vitamin C and AHA in a topical serum, compared to the reference ingredient in the management of melasma. (Sponsored by L'ORéAL DERMATOLOGICAL BEAUTY)	View	133322
Dr Paula ROSSO MILLAN	Enhancing Skin Quality: HA-based RHA1 treatment followed by skin redensification with R1– A prospective, multicenter, interventional study Status (Sponsored by TEOXANE LABORATORIES)	View	135106
Dr Peggy SEXTIUS	DISCOVERY OF 2-MERCAPTONICOTINOYL GLYCINE (Sponsored by L'ORéAL DERMATOLOGICAL BEAUTY)	View	134846
Dr Weimin SONG	Clinical Evaluation of the Moisturizing, Reduce Redness and Oil-Control Effects of a Lotion Containing Azelaic Acid, Alpha-Arbutin with Botanical Ingredients on Sensitive Oily to Combination Skin (Sponsored by L'ORéAL DERMATOLOGICAL BEAUTY)	View	133317
Dr Michela STARACE	The world's first device that stops hair loss and promotes its regrowth (Sponsored by APS SRL)	View	134941
Dr Agnieszka SUROWIECKA	Scar Management with Finexel (Sponsored by SNJ)	View	135918
Dr Luiz Eduardo TOLEDO AVELAR	Physicochemical properties of two poly L-lactic acid dermal fillers: potential impact on their biological properties (Sponsored by GALDERMA)	View	134949
Prof Alexander TURKEVYCH	POST-COMBAT BURNS AND SCARS TREATMENT: UKRANIAN EXPERIENCE (Sponsored by BIOFORMULA)	View	134998
Dr Alan WIDGEROW	A randomized, comparative study describing the gene signatures of Poly-L-Lactic Acid (PLLA-SCA) and Calcium Hydroxylapaptite (CaHA) in the treatment of nasolabial folds (Sponsored by GALDERMA)	View	134948
Dr Jinyuan YAN	A TOPICAL FORMULA CONTAINING PROXYLANE AND NIACINAMIDE AUGMENTS THE ANTI-AGEING BENEFITS OF A NON-ABLATIVE LASER TREATMENT (Sponsored by L'ORéAL DERMATOLOGICAL BEAUTY)	View	135541
Prof Bin YANG	Clinical Evaluation of Two Topical Products Containing Blueberry, Purple Rice Extract and Pro-xylane in Combination in Chinese Females with Mild-to-Moderate Facial Aging_(Sponsored by L'ORéAL DERMATOLOGICAL BEAUTY)	View	133318
Dr Jeong Hyun YOON	Tissue changes over time after polydioxanone thread insertion: An animal study with pigs (Sponsored by N-FINDERS)	View	135459
Dr Alisar S ZAHR	Novel Pathway in Enhancing Patient Comfort Post-Procedure with a Topical Treatment (Sponsored by REVISION SKINCARE)	View	135636
Dr Hua ZHONG	Clinical Evaluation of a Topical Antioxidant Serum Containing Resveratrol, Baicalin, and Vitamin E in Photodamaged Facial Skin. (Sponsored by L'ORéAL DERMATOLOGICAL BEAUTY)	View	133319

IMCAS World Congress 2024
Program

FOCUS ON INDUSTRY SPONSORED E-POSTER

Recommended sessions

IMCAS World Congress 2024 Program

FOCUS ON INDUSTRY SPONSORED E-POSTER

Recommended sessions

IMCAS World Congress 2024
Program